

Thursday - Saturday September 9-11, 2004; World Conference-Program

Thursday September 9, 2004

02:00 PM Session 1: The basis of antiinfective treatment

- 02:00 PM Pharmacokinetics and tissue penetration of antiinfectives
O. Cars, Uppsala, Sweden
- 02:20 PM Extra vs. intracellular penetration of antiinfectives
P. Tulkens, Louvain, Belgium
- 02:40 PM Microdialysis studies in healthy volunteers and patients
M. Müller, Vienna, Austria
- 03:00 PM In vitro and in vivo models of infection
W.A. Craig, Madison, USA
- 03:20 PM Summary and discussion by chairmen

03:30 PM Coffee Break

Sponsors' booths
Paul-Ehrlich-Exhibition
Ehrlich dye laboratory

04:00 PM Session 2: Principles of dosing and methods of individualization

- 04:00 PM Why sex and age are unimportant – a pharmacokinetic perspective
N. Holford, Auckland, New Zealand
- 04:20 PM Drug monitoring to optimize therapy
R. Jelliffe, Los Angeles, USA
- 04:40 PM PK/PD Optimization of antiinfectives by adaptive feedback control
A. Forrest, Buffalo, USA
- 05:00 PM Population PK and Monte Carlo Simulation
G.L. Drusano, Albany, USA
- 05:20 PM Summary and discussion by chairmen

05:30 PM End of presentations on Thursday

06:00 PM Opening Ceremony at the Althoff - Frerich Hall

07:45 PM Reception at the Ehrlich Plaza

Friday September 10, 2004

07:00 AM

Registration
Sponsors' booths
Paul-Ehrlich-Exhibition
Ehrlich dye laboratory

08:00 AM

Session 3: Antiinfectives' drug development and regulatory processes

08:00 AM Guidelines of FDA and EMEA for clinical studies
 H. Kemmler, Bern, Switzerland

08:20 AM Predicting drug interactions
 L.Z. Benet, San Francisco, USA

08:40 AM Adverse events and antiinfectives' drug interactions –
 lessons of the last 20 years
 R. Stahlmann, Berlin, Germany

09:00 AM Summary and discussion by chairmen

09:10 AM

Coffee break

Sponsors' booths
Paul-Ehrlich-Exhibition
Ehrlich dye laboratory

09:30 AM

Session 4: Antifungals and antivirals

09:30 AM Antifungals
 A. Louie, Albany, USA

09:55 AM Antivirals
 G.L. Drusano, Albany, USA

10:20 AM Summary and discussion by chairmen

Friday September 10, 2004

02:05 PM Session 5: Special populations and clinical pharmacodynamics

- 02:05 PM Dosing issues in neonates and children
J.N. v. d. Anker, Washington, USA
- 02:25 PM Dosing of antiinfectives in special populations
H. Derendorf, Gainesville, USA
- 02:45 PM Dosing guidelines in patients with renal replacement
F. Thalhammer, Vienna, Austria
- 03:05 PM Summary and discussion by chairmen

03:20 PM Session 6: Treatment of infection according to site of infection

- 03:20 PM Dosing of antibiotics in skin and soft tissue infections
W. Graninger, Vienna, Austria
- 03:40 PM Dosing of antibiotics in urinary tract infections
K.G. Naber, Straubing, Germany
- 04:00 PM Dosing of antibiotics in respiratory tract infections
H. Lode, Berlin, Germany
- 04:25 PM Sepsis and other difficult conditions
T. Welte, Hannover, Germany
- 04:45 PM Summary and discussion by chairmen

05:00 PM End of presentations on Friday

**07:00 PM Ceremonial Gala Evening to celebrate Paul Ehrlich's 150th Birthday
(ends 11:30 PM)**

Saturday September 11, 2004

07:00 AM Registration

Sponsors' booths
Paul-Ehrlich-Exhibition
Ehrlich dye laboratory

08:30 AM Session 7: Dosing of antiinfectives

- 08:30 AM Hepatitis C – dosing regimens
S. Rossol, Rüsselsheim, Germany
- 08:50 AM Anti-tuberculosis treatment
R.S. Wallis, Newark, USA
- 09:10 AM Preventing antimalarial resistance
N. White, Bangkok, Thailand
- 09:30 AM Treatment and dosing of *Helicobacter pylori* infection –
when pharmacology meets clinic
P. Malfertheiner, Magdeburg, Germany
- 09:50 AM Summary and discussion by chairmen

10:00 AM Coffee break

Paul-Ehrlich-Exhibition
Colors and art – artists use Ehrlich's colors
Ehrlich dye laboratory

10:15 AM Session 8: Views in PK/PD and controversies

- 10:15 AM Vancomycin – Clinical pharmacodynamics in hospitalized patients
J.J. Schentag, Buffalo, USA
- 10:35 AM Protein binding – a microbiologist's view
B. Wiedemann, Bonn, Germany
- 10:50 AM Protein binding – a pharmacologist's view
H. Derendorf, Gainesville, Florida
- 11:05 AM Can resistance be prevented?
P.C. Appelbaum, Hershey, USA
- 11:25 AM Can resistance be prevented? / Intermittent vs continuous infusion –
ISAP position
J.W. Mouton, Nijmegen, Netherlands
- 11:50 AM Effectiveness of antiinfectives: do not forget the patient!
J.C. Pechère, Geneva, Switzerland
- 12:05 PM Summary and discussion by chairmen

Saturday September 11, 2004

01:30 PM “Magic Bullets” – Tools and perspectives

- 01:30 PM Pharmacokinetics and pharmacodynamics –
 concepts in drug development from Ehrlich to modern PK/PD
 L.Z. Benet, San Francisco, USA
- 02:00 PM The role of animal experimentation in designing
 antiinfective therapy from Ehrlich to today’s methods
 W.A. Craig, Madison, USA
- 02:30 PM The challenges of advancing Paul Ehrlich's
 chemotherapeutic principles in the present era
 R.C. Moellering, Boston, USA
- 03:00 PM Ehrlich's modern dream – therapeutic antibodies
 B. Groner, Frankfurt/M, Germany

03:30 PM End of WCDA: Closing remarks

K.G. Naber, Straubing, Germany

Oral Presentations

Thursday, September 09, 2004

Antiinfectives - new and known non-synthetic compounds
Clinical studies and use of antibiotics
Pharmacokinetics and tissue penetration of antiinfectives
Antivirals - clinical studies
Resistance to antiinfectives
Mechanisms of pharmacological and biochemical action of antiinfectives
Antiinfectives - new and known synthetic compounds
Pharmacodynamics and experimental therapy of antiinfectives
Pharmacokinetics and tissue penetration of antiinfectives
Targeted delivery of antineoplastic agents
Antineoplastic agents - new and known synthetic compounds
Mechanism of tumor development and growth
Antineoplastic agents - new and known non-synthetic compounds
Antineoplastic agents - clinical studies
Blood brain barrier
Adverse events, interactions and toxicity of antiinfectives
Clinical studies and use of antibiotics
Role of cells and their staining by dyes
Clinical studies and use of antibiotics
Antiinfectives - new and known synthetic compounds

Friday, September 10, 2004

Mechanisms of pharmacological and biochemical action of antiinfectives
Clinical studies and use of antibiotics
Pharmacokinetics and tissue penetration of antiinfectives
Antiinfectives - new and known synthetic compounds
Antineoplastic agents - new and known synthetic compounds
Antivirals & Antifungals - clinical studies
Pharmacodynamics and experimental therapy of antiinfectives
Pharmacokinetics and tissue penetration of antiinfectives
Diagnostic tests in cancer / adverse events of cancer treatment & Adverse events of antineoplastic compounds
Antiinfectives - new and known non-synthetic compounds
Mechanism of tumor development and growth
In vitro action of antimalarials
Mechanisms of pharmacological importance
Targeted delivery of antineoplastic agents
Analytical techniques
Role of cells and their staining by dyes
Antineoplastic agents - new and known synthetic compounds
Targeted delivery of antineoplastic agents
Antimalarial compounds - clinical studies
Adverse events, interactions and toxicity of antiinfectives
Antineoplastic agents - new and known non-synthetic compounds & Antineoplastic agents - clinical studies
Clinical studies and use of antibiotics
Clinical studies and use of antibiotics

Saturday, September 11, 2004

Microbiology & Resistance to antiinfectives
Antiviral agents
Mechanisms of pharmacological importance
Clinical studies and use of antibiotics
About mechanisms and Magic Bullets
Blood brain barrier
Mechanisms of action of antineoplastic agents including resistance
Agents involving the immune system
Design of drug delivery & Vaccination

Oral Presentations

Thursday, September 09, 2004

Category: Antiinfectives - new and known non-synthetic compounds

07:30 - 09:15 AM Room assignment will be printed in the final program

- 353 Chemical Approaches for Improving ADME Properties of Lipoglycopeptide Antibiotics.
MU Y, LINSELL M, LEADBETTER M, FATHEREE P, NODWELL M, TRAPP S, LAM B, PACE J, SHAW JP, JUDICE K
Theravance Inc. South San Francisco, USA.
- 400 Therapeutic and Biotechnological Applications of Ribosomally Synthesized Antimicrobial Peptides.
PAPAGIANNI M
Department of Hygiene and Technology of Food of Animal Origin, School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 548 Antimicrobial Activity of Chitosan including practical application.
Seichi Tokura, Tetsuaki Tsuchido, Kaoru Negoro* and Hiroshi Tamura
Faculty of Engineering and HRC, Kansai University, Suita, Osaka, Japan
*Negoro Sanngyo Co. Ltd. Kishiwada, Osaka, Japan.
- 593 Medicinal Plants of Southeast Asia: A Source for New Antibiotics?
Christophe Wiart
Department of Pharmacy, Faculty of Medicine, University of Malaya, Malaysia.
- 139 Why has there been so little success in finding new high activity antimicrobial compounds from plants?
ELOFF JN
Programme for Phytomedicine, University of Pretoria, South Africa.
- 119 CAY-1, a Plant-produced Saponin Active against Phytopathogenic and Medical Pathogenic Fungi.
A. DE LUCCA¹, S. BOUE¹, J. BLAND¹, L. WARTELLE¹, C. SELITRENNIKOFF², S. RENAULT², M. CUSHION³, T. CLEVELAND¹, and T. WALSH⁴.
¹Southern Regional Research Center, USDA, New Orleans, LA USA; ²Mycologics, Inc, Aurora, CO USA; ³Univ. of Cincinnati College of Medicine, Cincinnati, OH USA; ⁴National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
- 562 *Kola acuminata* proanthocyanidins: a class of potent anti-trypanosomal drugs effective against the infective form of *Trypanosoma brucei*.
URADE Y¹, Kubata BK^{1,2,*}, Murakami N³, Merkel P⁴, Kabututu Z^{1,3}, Martin SK², Duszenko M⁴
¹Osaka Bioscience Institute, Osaka, Japan;
²US Army Medical Research Unit-Kenya, Nairobi, Kenya;
³Osaka University, Osaka, Japan;
⁴Universität Tübingen, Tübingen, Germany.

Category: Clinical studies and use of antibiotics

07:30 - 09:15 AM Room assignment will be printed in the final program

- 230 Abnormal acquisition of intestinal flora in surgical neonates and the efficacy of synbiotic therapy for pediatric surgical patients with intestinal or respiratory failure.
KANAMORI Y¹, HASHIZUME K¹, SUGIYAMA M¹, TOMONAGA T¹, YUKI N², TAKAHASHI T², MOROTOMI M².
1)Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo JAPAN
2)Yakult Central Institute for Microbiological Research, Tokyo JAPAN.
- 260 Outpatient Management of Low Risk Pediatric Oncology Patients with Fever and Neutropenia. How Do We Move from Clinical Trials to Clinical Practice?
KLAASSEN RJ
Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
- 483 The safety and efficacy of thalidomide in childhood tuberculous meningitis.
SCHOEMAN JF¹, SPRINGER P¹, JANSE VAN RENSBURG A¹, SWANEVELDER S², HANEKOM W³, HASLETT P⁴, KAPLAN G⁵
¹Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital; ²Biostatistics Unit, Medical Research Council; , Cape Town, South Africa
³Department of Pediatrics, University of Miami, Miami, Florida, ⁴Department of Microbiology and Immunology, University of Miami, Miami, Florida, and ⁵Public Health Research Institute, International Center for Public Health, Newark, NJ, USA.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 035 Day-Care Based Management of Severe Pneumonia in Children with Injection Ceftriaxone.
ASHRAF H¹, ALAM NH¹, MAHMUD R², JAHAN SA¹, HAQUE F³, GYR K⁴ ¹ICDDR,B
Centre for Health and Population Research, Dhaka, Bangladesh; ²Radda MCH-FP Centre,
Dhaka, Bangladesh, ³Institute of Child Health & Shishu Hospital, Dhaka, Bangladesh,
⁴University of Basel, Switzerland.
- 355 Updates on Antibiotic prophylaxis in Surgical Patients.
Nader D. Nader
FCCP
- 453 New Applications of Co-trimoxazole Therapy (Review).
ROZIN A, MILITIANU D, EDOUTE Y
Rambam Medical Center and B. Rappaport Faculty of Medicine, Israel-Technion Institute of
Technology, Haifa, Israel.
- 267 IgY (Immunglobuline from egg-Yolk) - a tool to fight the emerging problem of antibiotic
resistance.
KOLLBERG H¹, LARSSON A², CARLANDER D².
¹CF Center, University Children's Hospital, Uppsala, Sweden, ²Dep. Med sciences, University
Hospital, Uppsala, Sweden.

Category: Pharmacokinetics and tissue penetration of antiinfectives

07:30 - 09:15 AM

Room assignment will be printed in the final program

- 521 Barriers to Magic Bullets; The Permeability of Mucosal Tissue to Therapeutic Agents.
SQUIER CA, KREMER M, WERTZ PW
Dows Institute for Dental Research, University of Iowa, Iowa City, Iowa, USA.
- 440 Tissue Penetration and Behaviour of Antibiotics in Acute Pancreatitis.
MAS MR, TASCI I, ISIK AT
Gulhane Medical Faculty, Ankara, Turkey.
- 508 Excretion and Resorption by the Skin.
SIMON GA
Israel Institute for Biological Research, Ness Ziona, Israel.
- 168 Cefotaxime and Ceftriaxone Cerebrospinal Fluid Levels During Treatment of Bacterial
Meningitis in Children.
PN GOLDWATER
Microbiology & Infectious Diseases Department, The Women's & Children's Hospital, North
Adelaide, South Australia, Australia.
- 078 Estimation of Amikacin Pharmacokinetic Parameters for South African Children.
BOTHA JH, FORSYTH NB
Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
- 253 Designing Antibiotics Dosage Regimens in Neonates Based on Population
Pharmacokinetics (PPK): Comparative Study of Arbekacin (ABK), Vancomycin (VCM) and
Panipenem (PAPM).
KIMURA T¹, YAGO K¹, SUNAKAWA K¹
¹Kitasato University Hospital, Kanagawa, Japan.
- 452 Antiinfective drug monitoring: time for change ?
ROUVEIX B.
Service de Pharmacologie Clinique, Hôpital Cochin–St Vincent de Paul, Paris, France.

Category: Antivirals - clinical studies

08:00 - 09:00 AM

Room assignment will be printed in the final program

- 229 Adverse Effects on Brain Function caused by IFN- α –Evaluation from Quantitative-
Electroencephalograms (q-EEG) in IFN- α Treated Hepatitis C Patients-
KAMEI S¹, MATSUURA M², TANAKA N³, ARAKAWA Y³, KOJIMA T², MATSUKAWA Y⁴,
MIZUTANI T¹, MORIYAMA M³, HIRAYANAGI K⁵
Divisions of ¹Neurology, ³Gastroenterology and Hepatology, and ⁴Hematology and
Rheumatology, Department of Medicine, and Departments of ²Neuropsychiatry, and
⁵Hygiene and Public Health, Nihon University School of Medicine, Tokyo, Japan.
- 471 Selective Myeloid Cell Purging as a Novel Adjunct to Interferon- α +Ribavirin Combination
Therapy in Patients with High Plasma HCV Viraemia Resistant to Interferon: An Enhanced
Immune Function Against HVC.
Saniabadi AR¹, Sawada K², Hirata I¹, Fukunaga K.³
¹Japan Immunoresearch Laboratories; ²Fujimoto Hospital Medicine; ³Hyogo College of
Medicine, Japan.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 054 Treatment of HIV-1/AIDS Patients with CpG ODN May Stop the Pandemic.
BECKER Y
The Hebrew University of Jerusalem, Jerusalem, Israel.
- 378 Toxoplasmosis In HIV/AIDS Patients: A Current Situation.
NISSAPATORN VEERANOOT¹, LEE CHRISTOPHER², QUEK KIA FATT³, LEONG CHEE LOON², MAHMUD ROHELA¹, ABDULLAH KHAIRUL ANUAR¹
¹Department of Parasitology, ³Department of Social and Preventive Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia. ²Department of Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.

Category : **Resistance to antiinfectives**

08:15 - 10:15 AM **Room assignment will be printed in the final program**

- 584 *In vitro* Antimicrobial Resistance in Bacteria Exposed to Residue Level Exposures of Antimicrobial Drugs, Pesticides and Veterinary Drugs.
D KLEINER, SE KATZ, **PL WARD**
Cook College, NJAES, Rutgers, the State University of New Jersey, New Brunswick, NJ, USA.
- 144 Strategies for Containment of Antibiotic Resistance in Developing Countries – Lessons from South Africa.
ESSACK, SY
University of KwaZulu-Natal, Durban, South Africa.
- 095 Yearwise (1989-2003) prevalence of drug resistance to various drugs among gram negative bacilli isolated from hospitalized cases in Central India.
Chitnis S, Chitnis V, Hemwani N and Chitnis DS.
- 162 Isolation of Multidrug-Resistant *Stenotrophomonas maltophilia* from a Marine Cultured Fish.
FURUSHITA M^{1,2}, MAEDA T¹, OKAMOTO A², OHTA M², SHIBA T¹
¹Department of Food Science and Technology, National Fisheries University, Shimonoseki, Japan; ²Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- 237 Antibiogram of Bacteria from Slaughter Animals on the Data of Resistance Monitoring System in 2003.
J-KASZANYITZKY É, JÁNOSI, S
Central Veterinary Institute, Budapest, Hungary.
- 122 Antiparasitic Drug Resistance: Lessons from Ivermectin and a Model Nematode.
DENT JA¹
¹McGill University, Montreal, QC, Canada.
- 281 Evolution Of Drug Resistance In A University Hospital In Singapore (NUH).
KUMARASINGHE G, JAYASURYA A, LIM SM, CHOW C.
National University Hospital, Singapore.
- 338 Antimicrobial Usage Data in Humans and Food Animals from 1995 to 2001 in Kenya.
MITEMA, ES¹, KIKUVI, G¹
¹Pharmacology and Toxicology Laboratory, Faculty of Veterinary Medicine, University of Nairobi, Nairobi, Kenya.

Category: **Mechanisms of pharmacological and biochemical action of antiinfectives**

09:30 - 11:45 AM **Room assignment will be printed in the final program**

- 563 Anti-Inflammatory Activity of Macrolides and Fluoroquinolones on Human Endothelial Cells.
URIARTE SM¹, MOLESTINA RE¹, MILLER RD¹, RAMIREZ JA¹, SUMMERSGILL JT¹.
¹University of Louisville School of Medicine, Louisville, KY, USA.
- 358 Crystal Structure Based Assembly of the MexAB-OprM Multidrug Efflux Pump in *Pseudomonas aeruginosa*.
NAKAE, T¹, AKAMA, H¹, MATSUURA, T², TSUKIHARA, T², and NAKAGAWA, A²
¹Tokai University School of Medicine, Isehara, Japan; ²Osaka University Institute for Protein Research, Suita, Japan.
- 084 Polymyxin B-Mediated Selective Lipid Exchange: Implications in Antibacterial Action.
CAJAL Y¹
¹Universitat de Barcelona, Barcelona, Spain.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 324 Monosaccharide Lipid A Analogues; Their Potencial as Magic Bullets to Enhance Host Innate Immunity against Microbial Infections.
MATSUURA M
Department of Infection and Immunity, Jichi Medical School, Tochigi, Japan.
- 333 The effect of combined antimicrobial treatment on prokaryotic cells and on certain groups of eukaryotic cells.
MILANKOVITS M.
Hungarian National Institute of Genitourinary Medicine Foundation, Budapest, Hungary.
- 406 Mechanisms of Induction and Regulation of Gut Mucosal Immune Stimulation by Non-Pathogenic Bacteria.
Maldonado Galdeano C.^{1,2}, Dogi C.¹, Bibas Bonet M.E.^{1,2}, Chaves S¹. And **Perdigón G.**^{1,2}
¹CERELA, Chacabuco, Tucumán, Argentina.
²Cátedra de Inmunología, FBQyF, Universidad Nacional de Tucumán, Argentina.
- 409 The Interface of Triosephosphate Isomerase of *Trypanosoma cruzi* as a Target for the Development of New Drugs for Chagas' Disease.
PEREZ-MONTFORT R¹, **GOMEZ-PUYOU A¹**
¹Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México DF, México.
- 514 Forcing Nanoscopic Infectious Agents to Incorporate Antiinfectives by Exposure to Moderate Laser Light Intensities – Solutions Inspired by Nature.
SOMMER, AP
Central Institute of Biomedical Engineering, University of Ulm, Ulm, Germany.
- 542 A New Type of Magic Bullet? Therapeutic Agents that Modify Rather than Kill the Pathogen.
TAYLOR PW¹, **MUSHTAQ N¹**, **LUZIO JP²**
¹School of Pharmacy, London, United Kingdom; ²Cambridge Institute for Medical Research, Cambridge, United Kingdom.

Category: Antiinfectives - new and known synthetic compounds

09:30 - 11:30 AM

Room assignment will be printed in the final program

- 394 Structural Modification of Dibenzosuberanylpiperazine and Diphenylacetyl- piperazine Derivatives Mainly for Efficient Reduction of Chloroquine Resistance in *Plasmodium chabaudi*.
OSA Y¹, **KOBAYASHI S²**, **SATO Y¹**, **SUZUKI Y²**, **TAKINO K¹**, **HIKIMA Y¹**, **TAKEUCHI T²**, **MIYATA Y³**, **SAKAGUCHI M³**, **TAKAYANAGI H¹**, **NAGASE H¹**
¹Kitasato University, Tokyo, Japan, ² Keio University, Tokyo, Japan, ³ Pola Chemical Industries, Inc., Yokohama, Japan.
- 067 New pyrrole derivatives of BM 212: a new class of antimycobacterial agents.
Biava M^{1*}, **Porretta¹ GC**, **Pompei R²**, **Laconi S²**, **Manetti F³**, **Botta M³**
¹Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Università "La Sapienza", Rome
²Cattedra di Microbiologia Applicata, Facoltà di Scienze Matematiche Fisiche Naturali, Università degli Studi di Cagliari, Cagliari, Italy; ³Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Aldo Moro snc.
- 200 Development of Hexadecyloxypropyl-cidofovir: An Oral Drug for the Prevention and Treatment of Smallpox.
HOSTETLER, KY
Department of Medicine, University of California, San Diego and the San Diego VA Healthcare System, San Diego, California, USA.
- 505 Improving and Assessing the Effectiveness of Antiinfective Drugs by Molecular Design and Theranostic Devices.
SIA SK
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA (USA).
- 071 Evidence for in vitro trypanocidal activity of methylene blue, but in vivo failure.
Caroline Boda, Bertin Enanga, Bertrand Courtioux, Christian Breton, Bernard Bouteille
UPRES-EA 3174 Neuroparasitologie et neuroépidémiologie tropicale
Faculty of medicine, Limoges Cedex (France).
- 303 Antileishmanial Drug Discovery & Development: Experiences With Drug Candidate PX-6518.
MAES L¹, **COS P¹**, **VANDEN BERGHE D¹**, **VAN PUYVELDE L²**
¹Laboratory for Microbiology, Parasitology & Hygiene, University Antwerp, Belgium;
²Vietnamese Academy of Science and Technology, Hanoi, Vietnam.
- 092 New "Magic Bullets" and Hypermutability Leading to Cytotoxic Resistance Emergence in *Escherichia coli*.
CHEREPENKO YI¹, **POTYAHAYLO AL¹**, **HOVORUN DM¹**
¹Institute of Molecular Biology and Genetics, Kyiv, Ukraine.

- 500 Prolonging the action of protein and peptide drugs by a novel approach of reversible PEGylation.
HAIM TSubery^{1,2}, MARINA MIRONCHIK¹, MATI FRIDKIN² AND YORAM SHECHTER¹
Departments of ¹Biological Chemistry and ²Organic Chemistry
The Weizmann Institute of Science, Rehovot, Israel.

Category: Pharmacodynamics and experimental therapy of antiinfectives

10:00 - 11:45 AM Room assignment will be printed in the final program

- 382 Monte Carlo Simulation versus *S.pneumoniae* of Levofloxacin 500mg, 750mg and 1000mg Once Daily Compared to Gatifloxacin 200mg and 400mg Once Daily Administered to Hospitalized Patients with Community Acquired Pneumonia (CAP): Dose and Age Stratification Study.
NOREDDIN AM^{1,2}, MARRAS TK⁴, CHAN CK⁴, HOBAN DJ^{2,3} and Zhanel GG^{2,3}
¹College of Pharmacy, University of Minnesota, Duluth, MN, USA; ²Faculty of Medicine, University of Manitoba; ³Health Sciences Centre, Winnipeg, MB; ⁴University of Toronto, Toronto, ON, Canada.
- 232 The impact of dosing frequency on patient compliance with antiinfectives – is there an evidence that once-daily dosage is a real solution?
KARDAS P¹
¹Medical University of Lodz, Lodz, Poland.
- 632 Mutant Selection Window.
DRLICA K, ZHAO X, LI X, WANG J, URBAN C, PERLIN D
Public Health Research Institute, Newark, NJ, USA
- 635 APC Anti-infective Action Is Augmented By APC Activation Of Protein C.
HASSOUNA HI, Penner J
Department of Medicine Michigan State University, Clinical Center East Lansing, MI, USA
- 451 Subcellular Drug Transport and the Effectiveness of Anti-infectives.
CHEN V¹, SHEDDEN K¹, ELLIOTT A¹ AND **ROSANIA GR**¹
¹University of Michigan, Ann Arbor.
- 388 Invasive group A *Streptococcus* infections followed by intranasal superinfection with influenza A virus in mice: Cure and prevention of lethal synergism.
OKAMOTO S^{1,3}, HAMADA S¹, KAWABATA S^{1,2}
¹Osaka University Graduate School of Dentistry, Suita-Osaka, Japan; ²Japan Science and Technology Agency, Kawaguchi-Saitama, Japan; ³Fukuoka Dental College, Fukuoka, Japan.
- 202 Treatment of *Toxocara canis* (Nematoda) Infection in Mice with Albendazole Incorporated into Liposome Carriers and Immunomodulator β -glucan.
HRČKOVA G, VELEBNY S, TOMAŠOVIČOVA O, ČORBA J
Parasitological Institute, Košice, Slovak Republic.

Category: Pharmacokinetics and tissue penetration of antiinfectives

10:30 - 11:45 AM Room assignment will be printed in the final program

- 105 Prediction of *in vivo* Human Pharmacokinetics from Nonclinical Data.
COOK CC
Baxter Healthcare, Round Lake IL, U.S.A.
- 408 EFFECT OF PARASITISM ON THE PLASMA DISPOSITION AND BIOAVAILABILITY OF DORAMECTIN IN LAMBS.
R. Pérez¹, C. Palma¹, I. Cabezas¹, L. Rubilar¹ and M. Arboix²
1: Facultad Medicina Veterinaria, Universidad de Concepción. Chillán - Chile. 2. Laboratorio Farmacología. Facultad Veterinaria. Universidad Autónoma de Barcelona, Bellaterra, Barcelona – España.
- 481 The Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Cross-Over Study in Healthy Volunteers.
IM RIGTER¹, **HG SCHIPPER**¹, RP KOOPMANS¹, HJM VAN KAN¹, HG FRIJLINK², PA KAGER¹, HJ GUCHELAAR¹
Academic Medical Center¹, University of Amsterdam, The Netherlands. University of Groningen², The Netherlands.
- 023 Antibiotic dosing in hepatic failure.
AMARAPURKAR DN
Department of Gastroenterology & Hepatology Bombay Hospital & Medical Research Centre, Mumbai India.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 299 A New Method to Predict Glomerular Filtration Rate and Adjust Drug Dose to Renal Function.
DONADIO C, CONSANI C, ARDINI M, BERNABINI G, CAPRIO F, GRASSI G, LUCCHESI A
Department of Internal Medicine – Nephrology, University of Pisa, Pisa, Italy.

Category: Targeted delivery of antineoplastic agents

11:45 AM - 02:00 PM Room assignment will be printed in the final program

- 294 Radiolanthanides for Pretarget and Conventional Radioimmunotherapy of Cancer: "Magic Bullets" versus "Smart Bombs".
LEWIS MR^{1,2,3}, MOHSIN H⁴, SIVAGURU G¹, JIA F¹, BRYAN JN¹, SHELTON TD⁵, HOFFMAN TJ⁵, CUTLER CS⁵, KETRING AR⁶, ATHEY PS⁷, SIMÓN J⁷, FRANK RK⁷, AXWORTHY DB⁸, JURISSON SS^{4,6}
¹Veterinary Medicine and Surgery, ²Radiology, ³Nuclear Science and Engineering Institute, ⁴Chemistry, ⁵Internal Medicine, ⁶Research Reactor Center, University of Missouri, Columbia, MO; ⁷The DOW Chemical Company, Freeport, TX; ⁸Aletheon Pharmaceuticals, Seattle, WA, USA.
- 439 Tumor-targeting of Antineoplastics using Nano-sized Drug Carriers and Focused Ultrasound.
Rapoport NY
University of Utah, Salt Lake City, Utah, USA.
- 014 Targeted Block Copolymer Drug Formulations for Oncology. Pre-Clinical and Clinical Experience.
ALAKHOV V
Supratek Pharma Inc., Dorval, Quebec, Canada.
- 292 $\alpha_v\beta_3$ -Integrin Targeted Camptothecin Conjugates.
LERCHEN HG¹, BAUMGARTEN J¹, LYNCH M², ALBERS M¹, BRUEGGEMEIER U¹, BURGER AM³, FIEBIG HH³.
¹Bayer HealthCare AG, Wuppertal, Germany; ²Bayer Corp. West Haven, USA, ³Oncotest GmbH, Freiburg, Germany.
- 301 Polymer therapeutics and cancer targeting principle, EPR-effect, ---- towards the magic bullets.
MAEDA H
Sojo University; Kumamoto University, and BioDynamics Research Laboratory, Kumamoto, Japan.
- 336 Extracellular and Intracellular Molecular Targeting of Drug Delivery System to Cancer Cells.
MINKO T
Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
- 370 "Targeted" Molecular Chemotherapy for Brain Tumors – Searching for the "Magic Bullet".
NEWTON HB
Division of Neuro-Oncology and Dardinger Neuro-Oncology Center, Ohio State University Medical Center and James Cancer Hospital & Solove Research Institute, Columbus, Ohio, USA.
- 098 Antisense DNAs: Targeted Genetic Medicine to Treat Cancer.
CHO-CHUNG YS
Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, MD, U.S.A.
- 051 Novel Oligonucleotides Inhibiting STAT3: Use in Hormone-Refractory Prostate Cancer.
BARTON BE, MURPHY TF, SHU P, HUANG HF, BARTON A
UMDNJ-New Jersey Medical School, Newark, NJ, USA.

Category: Antineoplastic agents - new and known synthetic compounds

12:00 - 01:30 PM Room assignment will be printed in the final program

- 104 Metal Based Anti-Cancer Drugs with Anti-Leukemic Thiobases and COX-inhibitors as Ligands.
CINI R
Department of Chemical and Biosystem Sciences and Technologies, University of Siena, Siena, Italy.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 344 An Innovative Approach for DNA Inactivation Using Combination of Phenothiazine Dyes, Rhodium Complex, and Visible Light.
Taj Mohammad
Purdue University, Department of Chemistry, and Department of Forestry and Natural Resources, IN, U. S. A.
- 519 Antineoplastic polyanions in cancer strategy.
SORIMACHI K
Dokkyo University School of Medicine, Mibu, Japan.
- 100 Enhanced Antineoplastic Efficacy *in vivo* of Lactone-Stabilized Camptothecins by Chemical Modification or Liposomal Delivery.
CHOW DSL¹, LI X¹, GONG L¹, WOLFE MD¹, GIOVANELLA BC²
¹College of Pharmacy, University of Houston, Houston, TX, USA; ²Stehlin Foundation for Cancer Research, Houston, TX, USA.
- 477 Destruction of Human Breast Cancer Cells by Tumor-targeted *Salmonella typhimurium*.
SCHATTEN H¹, FEA, A¹ and EISENSTARK, A¹
¹Dept. of Veterinary Pathobiology, Univ. of Missouri-Columbia, Columbia, MO, USA, ²Cancer Research Center, Columbia, MO, USA.
- 504 Development of Tumor-Activated Prodrugs of Cytotoxics (TAC).
SHIMMA N¹, ISHITSUKA H², OKABE H¹, UMEDA I¹, Hattori K¹, Miwa M¹
¹Chugai Pharm. Co. Ltd., Kamakura, Japan; ²Roche Diagnostics, Tokyo, Japan.

Category: Mechanism of tumor development and growth

12:00 - 13:30 PM

Room assignment will be printed in the final program

- 397 A Mathematical Model for Capillary Formation and Development in Tumor Angiogenesis.
PAMUK S
University of Kocaeli, Kocaeli, Turkey.
- 319 Intracellular Targeting of ¹⁰B compounds (¹⁰BSH) to Solid Tumors by Transferrin-Pegylated Liposomes (TF-PEG-LP), for Boron Neutron-Capture Therapy (BNCT).
Maruyama K¹, Kasaoka S¹, Takizawa T¹, Suzuki R¹, Utoguchi N¹, Yanagie H², Shinohara A³, Ono K⁴
¹Teikyo University, Kanagawa, Japan; ²University of Tokyo, Tokyo, Japan; ³Juntendo University, Tokyo, Japan; ⁴Kyoto University, Kyoto, Japan.
- 598 Mechanisms of Acute 5-Fluorouracil Chemotherapy-Induced Bone Growth Arrest in Young Rats.
CJ Xian, J Cool, BK Foster
Department of Orthopaedic Surgery, Women's and Children's Hospital, South Australia.
- 289 Detection of PDGFRB and ETV6 gene rearrangement in five cases of atypical chronic myeloid leukemia with 5q chromosome abnormalities.
LAZARIDOU A, MAVROUDI S, CHRISTAKIS JI
Cancer Hospital of Thessaloniki, Hematology Department, Greece.
- 480 Increasing tissue and cell penetration of therapeutic DNA by electrotransfer.
SCHERMAN D., BIGEY P, BLOQUEL C, TROLLET C
Laboratoire de Pharmacologie Chimique et Génétique, Faculté de Pharmacie Paris 5.
- 568 Inhibition of the RhoC GTPase-Mediated Inflammatory Breast Cancer Phenotype by Farnesyl Transferase Inhibitors.
GROH KE, RADUNSKY GS and VAN GOLEN KL
The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

Category: Antineoplastic agents - new and known non-synthetic compounds

12:45 - 03:15 PM

Room assignment will be printed in the final program

- 485 Selenium in Cancer Prevention and Therapy.
G.N.Schrauzer
University of California, San Diego, USA.
- 218 Characterization of Vitamin C: K₃ Induced Autoschizis in Human Bladder Cancer Cell Lines.
Jamison JM¹, Summers JL¹, Gilloteaux J², Buc-Calderon P³, Taper HS³
¹Summa Health System/ NEOUCOM, Akron, Ohio, USA; ²American University of the Caribbean, St. Maarten, Netherland Antilles, West Indies; ³Université Catholique de Louvain, Brussels-Woluwe, Belgium.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 201 Molecular Mechanism of Apoptosis Induction by Polyphenolic Compounds: Targeting Reactive Oxygen Species (ROS) and Mitochondria.
HOU D-X, Kubo M, Harazono K, Imamura I, Morishita A, Tong X, Uto T, Takeshita T, Fujii M.
Faculty of Agriculture, Kagoshima University, Kagoshima, Japan.
- 547 VEGF and its intrinsic inhibitory protein in human cancer.
TOI M¹, BANDO H¹, WEICH HA²
¹Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome, Tokyo, Japan
²German Research Center for Biotechnology, Braunschweig, Germany.
- 027 Conjunction of Small Interfering RNAs and Tumor-Penetrating Peptides Could Provide Novel Antineoplastic Agents.
Aoki Y^{1,2}, Oguchi S¹, Kumagai M¹, Suzawa K¹, Otsuki T², Miyamoto T², Hashizume K², Nakajima K³
¹Department of Internal Medicine, Matsumoto National Hospital, Matsumoto, Japan;
²Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School, Matsumoto, Japan; ³Peptide Institute, Inc., Osaka, Japan.
- 385 Screening of Natural Compounds for Inhibitory Activity on Tumor Cell Migration and Metastasis.
OGASAWARA M, MATSUBARA T, MATSUNAGA T, TAKAHASHI S, SUZUKI H
Toyama Prefectural Institute for Pharmaceutical Research, Toyama, Japan.
- 024 Leptospins Isolated from Marine Microorganism *Leptospira* sp. Inhibit DNA Topoisomerases and Induce Apoptosis in a Panel of Human Cancer Cell Lines.
Andoh T¹, Yanagihara M¹, Takahashi-Sasaki, N¹, Yamamoto S¹, Numata A², Yamori T³
¹Soka University Tokyo, ²Osaka University of Pharmaceutical Sciences, Osaka,
³Foundation for Cancer Research, Tokyo, Japan.
- 387 A Newly Identified Antineoplastic Molecule Derived from *Streptococcus pyogenes*: Involvement of Toll-Like Receptor (TLR) 4 Signaling.
OKAMOTO M
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan.
- 223 An antineoplastic compound from *Murdannia loriformis*.
JIRATCHARIYAKUL W¹, VONGSAKUL M², SUNTHORNSUK L¹, MOONGKARNDI P¹, SOMANABANDHU A¹, OKABE H³, FRAHM AW⁴
¹Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; ²Faculty of Science, Mahidol University, Bangkok, Thailand; ³Laboratory of Pharmacognosy and Plant Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; ⁴Dept. of Pharmaceutical Chemistry, Albert-Ludwigs-University, Freiburg, Germany.
- 093 Flying Bullets: Cytokine-like Antineoplastic Peptides from Insects.
CHERNYSH SI¹, PLESKACH VA², TULIN DV¹
¹St.Petersburg University, St.Petersburg, Russia; ²Institute of Cytology, St.Petersburg, Russia.

Category: Antineoplastic agents - clinical studies

02:00 - 04:35 PM Room assignment will be printed in the final program

- Individual dose adaptation in cancer chemotherapy
Jaehde U.
Inst. of Pharmacy, Dept. Clinical Pharmacy, University of Bonn, Germany.
- 160 Tissue Concentrations of some Antineoplastic Drugs in Cancer Patients.
FURLANUT M¹, FRANCESCHI L¹, GIORDA G², DE MANZONI G³, PASINI F³, CARTEI G⁴, CAGOL PP⁵
¹DPMSC University of Udine, Italy; ²CRO Aviano, Italy; ³General Surgery, University of Verona, Italy; ⁴Oncology Unit, General Hospital, Padua, Italy; ⁵General Surgery, University of Udine, Italy.
- 191 Magic Bullets Against Non-Small Cell Lung Cancer (NSCLC) are Becoming A Reality – Targets are in Sight.
HIRSH V¹
¹Royal Victoria Hospital, McGill University, Montreal, Canada.
- 350 Clinical Features, Response to Treatment, and Survival in Small Cell Lung Cancer: Effect of Histological Variability.
MORAN EM^{1,2}, IYER PR^{1,2}, KANESHIRO CA²
¹Department of Medicine, University of California, Irvine, Irvine, California; ²Long Beach VA Healthcare System, Long Beach, California, USA.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 428 Antiangiogenic Drugs for Chemotherapy of Bladder Tumors.
POSSATI L¹, MARGIOTTA C¹, ROCCHETTI R¹, CALZA R¹, TALEVI S¹, CORALLINI A²
¹Institute of Microbiology and Biomedical Sciences, Polytechnic University of Marche, Ancona, Italy; ²Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Italy.
- 450 Urinary Bladder Carcinogenesis after the Chernobyl Accident in Ukraine (Molecular Mechanisms).
ROMANENKO AM¹, VOZIANOV AF¹, FUKUSHIMA S²
¹Institute of Urology, Kiev, Ukraine; ²First Department of Pathology, Osaka City University Medical School, Osaka, Japan.
- 426 Sequential Chemotherapy in Advanced Colorectal Cancer: Results of Five Arms Study.
POPOV I¹, JELIC S¹, KRIVOKAPIC Z², MICEV M², JEZDIC S¹, ZDRAVKO Z¹, KEZIC I¹.
¹Institut of Oncology and Radiology, Belgrade, Serbia; ²First University Surgery Clinic, Belgrade, Serbia.
- 606 A Novel Chemotherapeutic Strategy against Colorectal Cancer Manipulating Dual Cell Death by Five-fluorouracil (5-FU); High-Dose Shorter plus Low-Dose Metronomic Regimen.
Yoshikawa R^{1,2}, Yanagi H¹, Noda M¹, Hashimoto-Tamaoki T^{2,3}, Kusunoki M⁴, and Yamamura T^{1,2}.
¹2nd Dept of Surg, ²Inst for Adv Med Sci, ³Dept of Genet, Hyogo College of Medicine, Nishinomiya, Hyogo; ⁴2nd Dept of Surg, Mie Univ, Tsu, Mie, JAPAN.
- 215 High-Dose Methotrexate With Leukovorin Rescue: Impact On The Management of Osteosarcoma.
JAFFE N¹
¹University of Texas M. D. Anderson Cancer Center, Division of Pediatrics, Houston, TX.
- 615 Latest Developments in Drug Treatment for Skin Cancers.
ZEITOUNI NC
Roswell Park Cancer Institute, Buffalo, New York, USA.

Category: Blood brain barrier

02:00 - 03:15 PM Room assignment will be printed in the final program

- 459 Amylin, the Regulation of Energy Homeostasis, and the Blood-Brain Barrier.
RUSHING PA
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
- 543 Brain-to-Blood Efflux Transporters for Hydrophilic Endogenous Substrates at the Blood-Brain Barrier as a CNS detoxifying system.
TERASAKI T¹, OHTSUKI S²
¹New Industry Creation Hatchery Center (NICHe), and ²Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan; ³CREST and SORST, Japan Science and Technology Agency, Japan.
- 128 Passage of Vasoactive Intestinal Peptide (VIP) Across the Blood-Brain Barrier and Comparison with Respect to the Passage of VIP/PACAP/Secretin Family Members.
DOGRUKOL-AK D¹, BANKS WA², TUNCEL N³, TORE F⁴, TUNCEL M¹
¹Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey, ²GRECC, Department of Internal Medicine, Division of Geriatrics, School of Medicine, Veterans Affairs Medical Center and Saint Louis University, St. Louis, MO, USA, ³Department of Physiology, Faculty of Medicine, Osmangazi University, 26480 Eskisehir, Turkey, ⁴Department of Physiology, Izzet Baysal Medical Faculty, Abant Izzet Baysal University, 14280 Bolu, Turkey.
- 468 Evidence of Pralidoxime Iodide (2-PAM) Penetration Across the Blood-Brain Barrier.
Sakurada K¹, Matsubara K², Ohta H¹, Ohmori T¹, Takatori T¹
¹National Research Institute of Police Science, Chiba, Japan; ²Asahikawa Medical College, Asahikawa, Japan.
- 251 Accumulation of Mini-plasmin in the Cerebral Capillaries Causes Destruction of the Blood-brain Barrier (BBB) in Influenza-associated Encephalopathy (IAE) in Mice: Proposal for a Therapeutic Target Molecule of Brain Edema of IAE.
KIDO H, YAMADA H, OKUMURA Y, YAO DF, CHEN Y, YANO M
Institute for Enzyme Research, The University of Tokushima, Tokushima, Japan.

Category: Adverse events, interactions and toxicity of antiinfectives

02:00 - 03:15 PM Room assignment will be printed in the final program

- 365 A Mathematical Model for the Efficacy and Toxicity of Aminoglycosides.
C. NEEF¹, A .H. Koop², S.A. van Gils²
¹Medisch Spectrum Twente, Enschede, The Netherlands; ² University of Twente, Enschede, The Netherlands.
- 551 Effect of Rapamycin on Hepatocyte Function and Proliferation Induced by Growth Factors.
TOMIYA T¹, INOUE Y¹, YANASE M¹, ARAI M¹, IKEDA H¹, TEJIMA K¹, NAGASHIMA K¹, NISHIKAWA T¹, WATANABE N¹, OMATA M¹, FUJIWARA K²
¹Department of Gastroenterology, University of Tokyo, Tokyo, Japan, ²Third Department of Internal Medicine, Saitama Medical School, Saitama, Japan.
- 286 Fatal Adverse Drug Reactions (ADR): A Forensic Perspective on the Use of Anti-microbial and Anti-neoplastic Agents.
Lau G
Centre for Forensic Medicine, Health Sciences Authority, Singapore.
- 555 Cytochrome P450 Enzyme Activity Depression in Critically ill Patients: Cause of Drug Interactions involving Antimicrobial Agents.
PATIPARN TOOMTONG¹
¹Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- 048 HAART-ASSOCIATED METABOLIC SYNDROME AND CARDIOVASCULAR RISK.
Giuseppe Barbaro, MD, **Giorgio Barbarini**¹
Department of Medical Pathophysiology, University of Rome "La Sapienza", Italy.
¹Department of Infectious and Tropical Disease, Policlinico S.Matteo, University of Pavia, Italy.

Category: Clinical studies and use of antibiotics

02:15 - 03:30 PM Room assignment will be printed in the final program

- 430 Consumer knowledge and demand for antibiotics; a Sri Lankan experience.
Premaratna R., Weerasinghe M., Vipulanayake T., Perera C., Balasooriya H. de Silva H.J.
Department of Medicine, Faculty of Medicine, University of Kelaniya, Sri Lanka.
- 525 State of the Art: Lyme Disease and the Legacy of Paul Ehrlich.
STRICKER RB¹, LAUTIN A², BURRASCANO JJ³
¹California Pacific Medical Center, San Francisco, CA, USA; ²New York University School of Medicine, New York, NY, USA and ³East End Medical Associates, East Hampton, NY, USA.
- 179 A Multispecies Biofilm Model Allows Prediction of Clinically Effective Concentrations of Antimicrobials in Oral Care Products.
B. Guggenheim¹, T. Boyd² and A. Gaffar²
¹University of Zurich, Institute for Oral Biology, Switzerland, ²Colgate Palmolive Company, Piscataway, NJ, USA.
- 356 Role of Antiinfectives in the Treatment of Periodontitis.
NAGASAWA T¹, KOSHY G¹, ISHIKAWA I¹
¹Periodontology, Department of Hard Tissue Engineering, Graduate School, Tokyo Medical and Dental University.
- 097 Antibiotics in the Management of Acute Pharyngitis/Tonsillitis - Survey of Family Physicians in Northeastern Poland.
Chlabicz S, Oltarzewska AM, Pytel-Krolczuk B
Medical University Bilystok, Bialystok, Poland.

Category: Role of cells and their staining by dyes

03:30 - 05:15 PM Room assignment will be printed in the final program

- 359 Staining Bacterial Cells: From Ehrlich to the Present.
NANNINGA N
Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
- 109 CELL STAINING WITH TRADITIONAL TURKISH MADDER ROOT.
CÜCER N¹, GÜLER N², YAMAMQGLU N¹, DEMIRTAS H¹
¹Erciyes University, Medical Faculty, Medical Biology Department. Kayseri-TURKEY
²Erciyes University, Veterinary Faculty, Pharmacology Department, Kayseri-TURKEY.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 159 Application of Quantitative Structure-Activity Relationships (QSAR) to Dye Affinity for Natural Fibre: a Challenge for the Domain.
FUNAR-TIMOFEI S¹, **KURUNCZI L**², **SIMON Z**¹
¹Coriolan Dragulescu' Institute of Chemistry, Timisoara, Romania; ²Victor Babes' University of Medicine and Pharmacy, Timisoara, Romania.
- 015 Fluorescence dyes, a powerful tool for structural characterization of macromolecules and cells.
ALBANI JR
Laboratoire de Biophysique Moléculaire, Université des Sciences et Technologies de Lille, Villeneuve d'Ascq Cédex, France.
- 322 Intermolecular Interactions of Functional Dyes in the Solid State – Color Polymorphism in Fluorescent Pyazine Dyes –
MATSUMOTO S¹, **UCHIDA Y**¹, **YANAGITA M**²
¹Yokohama National University, Yokohama, Japan; ²Nippon Soda Co., Ltd., Chiba, Japan.
- 636 Bifunctional effect of 17 β -estradiol on macrophage.
HONG MIN, **ZHU QUAN**
National Standard Lab of Pharmacology for Chinese Materia Medica, Nanjing, China.
- 580 The Use of Dyes in the Study of Microencapsulated Pheromone for Control of Oriental Fruit Moth.
Waldstein DW¹, **Gut L**²
¹Missouri State Fruit Experiment Station, SW Missouri State University, Missouri, USA
²Michigan State University, Michigan USA.

Category: Clinical studies and use of antibiotics

03:45 - 05:30 PM

Room assignment will be printed in the final program

- 236 Antibiotic treatment of respiratory infections in cystic fibrosis (CF) – the Stockholm policy and perspective.
KARPATI F, **Hjelte L**
Stockholm CF Centre, Children's Hospital, Karolinska University Hospital, Huddinge, Sweden.
- 364 Hepatocyte growth factor is a rapid therapeutic indicator within the first day of treatment in pneumonia.
NAYERI F¹, **ABEDNAZARI H**, **MILLINGER E**¹, **BRUDIN L**²
University Hospital, Linköping¹ and County Hospital, Kalmar², Sweden.
- 185 Role of different risk factors in the development of Bronchial asthma in Bangladesh: an age, sex and economic STATUS MATCHED PROSPECTIVE STUDY.
M Rashidul Hassan¹, **AKM Fazlur Rahman**², **ARM Luthful Kabir**², **M Ali Hossain**¹, **Asif M Mahmud**¹, **M Ruhul Amin**³, **Kazi S Bennoor**¹, **M Mostafizur Rahman**¹ et al
1.NIDCH, Dhaka. 2. ICMH, Dhaka. 3. BICH, Dhaka: Bangladesh.
- 060 Ehrlich's Theory Of Drug Action And Anti-tuberculous Gold Therapy.
TG BENEDEK
University of Pittsburgh, Pittsburgh, PA.
- 304 Antibiotics in nosocomial infection and Culture sensitivity - An experience over 25 years.
A.K.Mahapatra
Dept.of Neurosurgery, AIIMS, New Delhi-110029, India.
- 231 Impact of Extended Spectrum β -Lactamase Producers in the Management of Nosocomial Infections.
REBA **KANUNGO***, **ANANTHKRISHNAN**, **SHANMUGANATHAN**, **SANJAYBHATTACHARYA**, **S.KUMAR**, **RENU MATHEW***, **SHASHIKALA***, **&SRINIVASAN***
Department of Clinical Microbiology, Pondicherry Institute of Medical Sciences*, JawharlallInstitute of Medical Education and Research Pondicherry India.
- 411 Beta-Lactam/Beta-Lactamase Inhibitor (BLBI) Antibiotics are a Rational Choice for Treatment of Serious Infection with Extended-Spectrum Beta-Lactamase (ESBL) producing Bacteria.
PETERSON, LR
Evanston Northwestern Healthcare Research Institute and Northwestern University, Evanston, IL, USA.

Category: Antiinfectives - new and known synthetic compounds

03:45 - 05:30 PM

Room assignment will be printed in the final program

- 085 Anti-Microbial Efficacy of Hydroxyapatite-Chlorhexidine Coated External Fixation Pins.
CAMPBELL, AA¹, LI, XS¹, NELSON, BJ^{2*}, BOTTONI, C³, DEJONG, ES^{4*}, BROOKS, DE⁴
¹ Pacific Northwest National Laboratory, Richland WA
² Dwight D. Eisenhower Army Medical Center, Ft Gordon, GA
³ Keller Army Community Hospital, West Point, NY
⁴ U.S. Army Institute of Surgical Research, Fort Sam Houston TX.
- 106 Antimicrobial Drug Discovery: Need For A More Integrated Approach !
COS P¹, VANDEN BERGHE D¹, PIETERS L², MAES L¹
¹ Laboratory for Microbiology, Parasitology and Hygiene, ² Laboratory for Pharmacognosy and Phytochemistry, University of Antwerp, Belgium.
- 121 Ultrastructure of Tissue Barriers and Synthesis of Anti-Infectives Designed to Penetrate Them.
MISTLBERGER K¹, KREMSER C², PASCHKUNOVA I³, SÖLDER E⁴, WIESER E¹, GALANSKI M³, BARTSCH G⁵, KEPPLER B³, JASCHKE W², HUGL B⁵, BUCHBERGER W⁷, TALASZ H⁸ & **DEBBAGE P**¹
Depts. ¹Histol. Mol. Cell Biol., ²Radiol., ⁶Vasc. Surg., Clinical Chem. Biochem.; Clinics of ⁴Ob. Gyn., ⁵Urol., Medical Univ.; ⁷Tirol Land Hosp. Innsbruck, Austria; ³Inst. Inorg. Chem., Univ. Vienna, Austria.
- 389 A New Class of Potent Dual Acting Gyrase and Topoisomerase IV Inhibitors.
OLSON E¹, CHARIFSON P¹, GRILLOT A-L¹, GROSS C¹, GROSSMAN T¹, MANI N¹, MOORE J¹, NICOLAU D², PARSONS J¹, STAMOS D¹, TESSIER P²,
¹Vertex Pharmaceuticals Inc., Cambridge, MA, U.S.A; ²Hartford Hospital, Hartford, CT, U.S.A.
- 569 A novel tetramethylpiperidine-substituted phenazine (B4125) with activity against multiple drug-resistant Gram-positive bacteria.
VAN RENSBURG CEJ¹, O'SULLIVAN JF², HUYGENS F³.
¹University of Pretoria, Pretoria, South Africa, ²University College Belfield, Dublin, Ireland, ³Queensland University of Technology, Brisbane, Queensland.
- 047 Antifungal and Antimycobacterial Activity of New Imidazole and Triazole Derivatives. A Combined Experimental and Computational Approach.
ZAMPIERI D¹, MAMOLO MG¹, VIO L¹, FERRONE M², PRICL S², SCIALINO G³, and **BANFI E**³
¹Dept of Pharmaceutical Sciences; ²Dept of Chemical, Environmental and Raw Materials Engineering; ³Dept of Biomedical Sciences Microbiology Sect, University of Trieste, Trieste, Italy.
- 052 Predicting In-Vitro Permeability of Antimycotics Using Quantitative Structure-Activity Relationship (QSAR) Models.
BASAK SC, MILLS D
Natural Resources Research Institute, University of Minnesota Duluth, Duluth, MN, USA.

Friday, September 10, 2004

Category: Mechanisms of pharmacological and biochemical action of antiinfectives

07:30 - 09:30 AM

Room assignment will be printed in the final program

- 491 The Role of Efflux Transporters in Drug Targeting.
SEELIG A
Biozentrum der Universität Basel, Basel, Schweiz.
- 334 Exploitation of Peptide and Amino Acid Permeases as Drug Transporters of Antifungals.
MILEWSKI M
Gdańsk University of Technology, Gdańsk, Poland.
- 113 The Mode of Action of Glutathione Peptides as Antiprotozoal Agents.
D'SILVA C¹, DAUNES S¹, TOMAS A², ALIBU V P³, CLAYTON C³
¹Department of Chemistry & Materials, Manchester Metropolitan University, John Dalton Building, Chester Street, Manchester, UK; ² Department of Molecular Immunology, Instituto for Molecular and Cell Biology, Porto, Portugal; ³ZMBH, Universität Heidelberg, Heidelberg, Germany.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 152 Kit for Instant Tc-99m Labeling of the Antimicrobial Peptide Ubiquicidin 29-41: A Specific Radiopharmaceutical for Bacterial Infection Imaging.
FERRO-FLORES G¹, ARTEAGA-MURPHY C², PALOMARES-RODRIGUEZ P¹, MELENDEZ-ALAFORT L³, PEDRAZA-LOPEZ M²
¹Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, México; ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, DF, México; ³Universidad Autónoma del Estado de México, México.
- 205 Infectomics: Creating Holistic Strategies for the Development of Antiinfectives against the Central Nervous System (CNS) Infection.
HUANG SH^{1,2}, ZENG FY², JONG A¹, WU CH¹, HUANG SZ²
¹Childrens Hospital Los Angeles University of Southern California, Los Angeles, USA;
²Shanghai Children's Hospital Shanghai Jiao Tong University, Shanghai, China.
- 343 Effect of Isoniazid (INH) on Viability, Cell Morphologies and Acid-fastness Properties of *Mycobacterium avium* NCTC 8559 During the Growth Cycle.
MOHAMAD S¹, IBRAHIM P²
¹School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia; ² School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
- 482 Focus on Albendazole for Echinococcosis.
Hans G. SCHIPPER
Academic Medical Center, Amsterdam, The Netherlands.
- 261 Limitations of Virtual Screening: Experimental and Computer-Aided Search for Novel Inhibitors of *E. coli* Methionine Aminopeptidase.
SCHIFFMANN R, **KLEIN CD**
FR 8.2 Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany.

Category: Clinical studies and use of antibiotics

07:30 - 09:30 AM Room assignment will be printed in the final program

- 149 First Line *Helicobacter pylori* Therapy – are Commonly Used Regimens the Most Appropriate Ones? A Review.
FARUP PG
Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, and Innlandet Hospital HF, Gjøvik, Norway.
- 316 Effect of Helicobacter Pylori (HP) Eradication in the Clinical Course of Recurrent Aphthous Stomatitis (RAS).
MARKOPOULOS AK
Aristotle University of Thessaloniki, Dept.of Oral Medicine and Maxillofacial Pathology, Thessaloniki, Greece.
- 326 EFFECTIVENESS OF ANTIINFECTIVES.
Ramona Mc Loughlin, Colm O'Morain
Adelaide & Meath Hospital, and Trinity College Dublin, Dublin.
- 010 Pattern of Antibiotic Therapy and Clinical Outcome in Acute Generalized Peritonitis in Semi-Urban and Rural Nigerian Community.
ADESUNKANMI A.R. K., BADMUS T.A., AGBAKWURU E.A.
Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
- 086 Reasons for Failure of Antibiotic Treatment in Patients with Pyogenic Liver Abscess (PLA).
CERWENKA H
Division of Visceral Surgery, Department of Surgery, Medical University of Graz, Austria.
- 498 A Prospective Study of Comparison of Efficacy of Two Combination Treatment Groups in Syndromic Treatment of Lower genital infections.
SHARMA JB¹, MITTAL S¹, RAINA U²
¹All India Institute of Medical Sciences, New Delhi, India; ² Lok Nayak Hospital, New Delhi, India.
- 574 Is Antiinfective Therapy the "Magic Bullet" in the Prevention of Preterm Delivery?
Vidaeff A
Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Medical School at Houston, Houston, USA.
- 412 Antibiotic treatment of acute pyelonephritis: are we asking the right questions?
MEZZA E¹, BURDESE M¹, COLLA L¹, CONSIGLIO V¹, TATTOLI F¹, MADDALENA E¹, SEGOLONI GP¹, PICCOLI G¹, **PICCOLI GB¹**.
Chair of Nephrology, Internal Medicine Department, University of Turin – Italy.

Category: Pharmacokinetics and tissue penetration of antiinfectives

07:30 - 09:35 AM Room assignment will be printed in the final program

- 112 Dose Adjustment of Ciprofloxacin in Renal Failure: Should we Reduce the Dose or Prolong the Administration Interval?
CZOCK D, KELLER F
University Hospital Ulm, Ulm, Germany.
- 124 Metabolism of Metronidazole in Early Stages of Chick Embryo - A Novel Model for Human Metabolism.
DEVARAKONDA R K, NARASIAH N AND VIDYASAGAR J
Cancer, Aging & Metabolism Research Division, Kakatiya University, University College of Pharmaceutical Sciences, WARNGAL, AP, India.
- 080 Tissue Penetration of Anti-infective Agents.
BROWN PD
Department of Basic Medical Sciences, Biochemistry section, University of the West Indies, Mona, Kingston, Jamaica.
- 209 Penetration of Anti-infectives into the Lung.
HUSSAIN, I and AMIN, MZ
Washington University St. Louis, MO USA.
- 330 Azithromycin (AZT) serum and mammary secretion concentrations after its intramammary (IMM) administration in healthy and mastitic cows.
MESTORINO N, TURIC E, PESOA J, ERRECALDE JO.
Department of Pharmacology. Facultad de Ciencias Veterinarias. Universidad Nacional de La Plata.
- 366 Antibiotic penetration of the blood-brain barrier pharmacokinetics in cerebrospinal fluid and neurotoxicity (Review).
Mirjana Nesin
Weill Medical College of Cornell University, New York City, N.Y., USA.
Tissue concentrations - what does it matter from a clinical point of view?
Scaglione F.
University of Milan, Milan, Italy.
- 368 Extended Interval Dosing of Aminoglycosides in Neonates is Safe and Effective: Systematic Review and Meta-Analysis of Controlled Trials.
NESTAAS E¹, BANGSTAD HJ², SANDVIK L², WATHNE KO²
¹Hospital of Vestfold, Tønsberg, Norway, ²Ullevål University Hospital, Oslo, Norway.

Category: Antiinfectives - new and known synthetic compounds

07:30 - 08:45 AM Room assignment will be printed in the final program

- 554 Search For A New Chemical Class Of Metallo-β-Lactamase Inhibitors: Reversing Bacterial Antibiotic Resistance.
TONEY JH, THOMAS, JD, MOLOUGHNEY, JG
Department of Chemistry and Biochemistry, Montclair State University, Upper Montclair, New Jersey, USA.
- 137 The Use of Antibiotics in Immobilized Form: A Controlled Drug Delivery System to Minimize the Risk of Drug Misuse/Misdose in Developing Countries.
EI Enshasy, H.A.
Mubarak City for Scientific Research, Alexandria, Egypt.
- 188 Design and Synthesis of Contact System Inhibitors for the Treatment of Infectious Diseases.
RUSSELL, W¹, FEX, T², BJÖRCK, L¹ and **HERWALD, H¹**
¹Section for Molecular Pathogenesis, Department of Cell and Molecular Biology, Lund University, Sweden and ²Orbichem, Lund, Sweden.
- 210 New Anti-infective Agents Developed by Novel Chemo-combination Strategy.
HWU JR¹, TSAY S-C²
¹National Tsing Hua University, Hsinchu, Taiwan, R.O.C.; ²Well-being Biochemical Corporation, Taipei, Taiwan, R.O.C.
- 363 Metal Complexes as Leishmanicidal Agents.
^aNAVARRO M, ^aCISNEROS-FAJARDO E, ^bMARCHAN E.
^aI.V.I.C. Centro de Química. Caracas. BIICA-U.D.O. Cumaná Venezuela.

Category: Antineoplastic agents - new and known synthetic compounds

07:30 - 09:20 AM Room assignment will be printed in the final program

- 244 Antitumor Active Metal Coordinated Compounds - New Concepts For Cancer Chemotherapy - A Review.
KEPPLER BK
Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.
- 030 Reactions of Potent Anti-Tumour Complex *trans*-[Ru^{III}Cl₄(ind)₂]⁻ with DNA-Relevant Nucleobase and Thioethers: an Insight into Biological Action.
ARION VB, EGGER A, REISNER E, CEBRIAN-LOSANTOS B, KEPPLER BK
Institute of Inorganic Chemistry of the University of Vienna, Austria.
- 183 Investigations into the Mechanism of Action of indazolium *trans*-[tetrachlorobis(1*H*-indazole)ruthenate(III)] – an Antineoplastic Ruthenium(III) Coordination Compound.
HARTINGER CG, SCHLUGA P, EGGER A, PONGRATZ M, ARION VA, JAKUPEC MA, GALANSKI M, KEPPLER BK
Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.
- 256 DNA Cleavage Activity of Diazonium Salts.
KIZIL M¹, INCE YILMAZ E², PİRİNÇÇİOĞLU N¹, AYTEKİN Ç¹, KIZIL G¹
¹Department of Chemistry, ²Department of Biology, Faculty of Science, Dicle University, Diyarbakır, Turkey.
- 401 STI 571 Bullets Ionizing Radiation in HNSCC.
Francisco S. Pardo, Weg Okenko, Joseph Aguilera, Jamie Milligan, Jean Wang
Departments of Biology, Radiation Biology, Otolaryngology, and Radiation Oncology. University of California, San Diego, and the Moores UCSD Cancer Center, San Diego, CA USA.
- 101 Inhibition of cyclo-oxygenase 2 (COX-2) enzyme in breast cancer.
CHOW LWC
Hung Chao Hong Integrated Centre for Breast Diseases, University of Hong Kong Medical Centre, Hong Kong, China.
- 175 Are 2'-deoxyadenosine esters potential antileukemic drugs?
GRIEB P¹, KRYCZKA T¹, ANDRZEJEWSKA M², STACHNIK K³, KAZIMIERCZUK Z¹.
¹Department of Experimental Pharmacology, Mossakowski MRC PAS, Warsaw, Poland; ²Institute of Chemistry, Agricultural University, Warsaw, Poland; ³Laboratory of Flow Cytometry, National Institute of Public Health, Warsaw, Poland.

Category: Antivirals & Antifungals - clinical studies

07:30 - 09:45 AM Room assignment will be printed in the final program

- 432 Combined Antiviral and Anti-inflammatory Therapy of Viral Pneumonia.
PRINCE GA¹, BOUKHVALOVA M¹, BLANCO J¹
¹Virion Systems, Inc., Rockville, Maryland, USA.
- 272 Antiviral maintenance therapy with interferon- α 2b and ribavirin for recurrent hepatitis C after liver transplantation-----clinical and morphological benefits in the long-term follow-up.
A. Kornberg, B. Küpper, A. Tannapfel, M. Hommann, U. Settmacher, J. Scheele.
- 042 Oral Valacyclovir Treatment in Herpetic Corneal Disease.
AVUNDUK AM, SÖZEN E, AKYOL N
Karadeniz Technical University, School of Medicine, Department of Ophthalmology. Trabzon-Turkey.
- 120 In-vivo Monitoring of Herpes Simplex Virus type 1 (HSV) Encephalitis with Positron Emission Tomography (PET).
BUURSMA AR¹, KLEIN HC², GARSEN J³, KEGLER D³, HOSPERS GAP¹, VAALBURG W¹, DE VRIES EFJ¹
¹Groningen University Hospital, Groningen, the Netherlands; ²Centre for Mental Health Winschoten, Winschoten, the Netherlands; ³National Institute for Public Health, Bilthoven, the Netherlands.
- 487 Use of HIV-1 p24 Antigen for Monitoring Continuous and Structured Antiretroviral Therapies and Implications for Therapeutic Vaccination.
SCHUPBACH J
Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland.
- 238 Prevention of Invasive *Candida* Infection in High-Risk Preterm Infants <1000 Grams Birth Weight.
D KAUFMAN, R BOYLE, KC HAZEN, JT PATRIE, M ROBINSON AND LB GROSSMAN
University of Virginia, Charlottesville, VA. USA.

- 472 SHOULD WE THINK FUNGUS IN POLYSYMPOMATIC PATIENTS ?
A randomised, double-blind trial with nystatin versus placebo in general practice
Santelmann H, Lærum E, Rønnevig J and Fagertun HE
Institutt for Allmenntmedisin og Samfunnsmedisin, Universitet i Oslo, Norge.
- 211 Antiinfectives Used for *Penicillium marneffe* Infection in HIV-Infected Patients: a Review.
IAMAROON A¹, PONGSIRIWET S¹, THOSAPORN W¹, VANITTANAKOM N²
¹Department of Odontology and Oral Pathology, Faculty of Dentistry; ²Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 347 Early Treatment of Candidiasis in Non-Neutropenic Critically Ill Patients.
NOLLA-SALAS M¹, **MONMANY J**², GICH I³, IBÁÑEZ-NOLLA J⁴
¹Institut de Recerca*. Emergency Department, Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona; ²Internal Medicine Department*; ³Department of Epidemiology*; ⁴Emergency Department, Hospital General de Catalunya, Sant Cugat del Vallès, Barcelona.
*Hospital de Sant Pau, Universitat Autònoma de Barcelona. Barcelona. Spain.

Category: Pharmacodynamics and experimental therapy of antiinfectives

08:00 - 09:30 AM Room assignment will be printed in the final program

- 146 The Importance of Pharmacokinetic/Pharmacodynamic (PK/PD) Knowledge Discovery in the Development of Antiinfective Agents.
Ette EI¹, Chu H-M¹, Ajayi FO².
¹Vertex Pharmaceuticals, Cambridge, MA., U.S.A., ²Proctor and Gamble, Pharmaceuticals Division, Cincinnati, OH., U.S.A.
- 212 FROM MAGIC BULLETS TO NANOTECHNOLOGY – WE HAVE COME A LONG WAY AND YET A LONG WAY TO GO FOR EFFECTIVE MANAGEMENT OF INFECTIOUS DISEASES.
Omer Iqbal, MD, FACC., Jawed Fareed, Ph.D, FACB.
Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.
- 064 Correlation between antibiotic pharmacokinetics and antibiotic resistance.
E Bergogne-Berezin
Bichat University, Masson, Paris, France.
- 174 Intracellular Penetration and Activity of Levofloxacin in *Staphylococcus Aureus* Infected Human Monocytes.
GRELLET J¹, NGUYEN H¹, SAUX MC¹, QUENTIN²
¹Pharmacokinetics Laboratory, ²Microbiology Laboratory, Bordeaux II University, Bordeaux, France.
- 235 Distribution of Metronidazole (MDZ) in Muscle Tissue of Healthy Volunteers (H) and Patients with Septic Shock (SS) and its Efficiency Against *Bacteroides fragilis* (Bf) in Vitro.
KARJAGIN J, PÄHKLA R, KARKI T, STARKOPF J
University of Tartu, Tartu, Estonia.
- 298 Non-antibiotic treatment of infections – some alternative strategies.
LJUNGH Å
Dept Medical Microbiology, Dermatology and Infection, Lund University, Lund, Sweden.

Category: Pharmacokinetics and tissue penetration of antiinfectives

08:50 - 10:35 AM Room assignment will be printed in the final program

- 621 Dosing Strategy for Antiinfectives in First-In-Human (FIH) Studies.
ZHU M
Clinical Drug Evaluation, Johnson & Johnson Pharmaceutical Research and Development LLC, New Jersey, USA.
- 644 Use of Modelling and Simulation in the development of Levofloxacin.
WEBER W, RUEPPEL D
Aventis Pharma Deutschland GmbH, Germany.
- 285 Influence of Sex on the Pharmacokinetics of Chosen Quinolone.
LAMPARCZYK H, KONIECZNA L, CHMIELEWSKA A
Medical University of Gdańsk, Gdańsk, Poland.
- 028 Amoxicillin (AMX) Clinical Pharmacokinetics (PK): past, present, and future.
ARANCIBIA A
Department of Pharmaceutical Sciences, University of Chile, Santiago, Chile.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 479 Pharmacokinetics and efficacy of old and new antifungal agents for the treatment of endogenous endophthalmitis.
SCHELENZ S
Norfolk & Norwich University Hospital, Norwich, United Kingdom.
- 575 Targeting of Amphotericin B using Lipid Nanospheres for the Treatment of Visceral Leishmaniasis.
VOBALABOINA V¹, VEERAREDDY PR¹, AND ALI N².
1. University College of Pharmaceutical Sciences, Kakatiya University, Warangal, A.P-INDIA.
2. Indian Institute of Chemical Biology, Jadavpur, Kolkata, INDIA.
- 199 Pharmacokinetics and effects of ribavirin by intravenous and intraventricular administration for the treatment of subacute sclerosing panencephalitis (SSPE).
Mitsuaki Hosoya¹, Hitoshi Suzuki¹, Shuichi Mori², Shiro Shigeta²
¹Department of Pediatrics and ²Department of Microbiology, Fukushima Medical University School of Medicine.

Category: Diagnostic tests in cancer / adverse events of cancer treatment & Adverse events of antineoplastic compounds

09:45 - 10:45 AM Room assignment will be printed in the final program

- 247 Enhancing the "Magic Bullet": Bispecific antibody-polymer probe technology for gamma imaging of small vascular lesions in vivo.
KHAW BA¹, TEKABE Y¹, DONAHAY T², JOHNSON LL².
¹Northeastern University, Boston, MA, USA, ²Rhode Island Hospital, Providence, RI, USA.
- 384 Prognostic and Predictive Biomarkers in Breast Cancer.
O'DRISCOLL L¹, KENNEDY SM², CROWN J^{1&2}, CLYNES M¹
¹National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; ²St Vincent's University Hospital, Dublin 4, Ireland.
- 257 The Protective Effect of Melatonin on Cisplatin Ototoxicity.
Ahmet Kizilay¹, M. Tayyar Kalcioğlu², Mustafa Iraz³, Ercument Olmez⁴, Mucahit Egri⁵, Orhan Ozturan⁶
^{1,2,6} Department of Otorhinolaryngology; ^{3,4}Department of Pharmacology; ⁵Department of Public Health; Inonu University School of Medicine, Malatya, TURKEY.
- 328 Intestinal permeability (IP) in the assessment of intestinal toxicity of cytotoxic drugs.
MELICHAR B, DVORÁK J, HYŠPLER R, ZADÁK Z
Charles University Medical School, Hradec Králové, Czech Republic.

Category: Antiinfectives - new and known non-synthetic compounds

09:45 - 11:00 AM Room assignment will be printed in the final program

- 079 The Magic Bullet Nisin: Structural Insights and an Additional Mechanism of Action?
Breukink E¹, Hasper H¹, Hsu, S-T D²
¹Department of Biochemistry of Membranes and ²Department of NMR Spectroscopy Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands.
- 545 Nontoxic, antifungal plant defensins interact with fungal-specific sphingolipids.
THEVISSEN K¹, WARNECKE DE², FRANCOIS IEJA¹, AERTS A¹, LEIPELT M², HEINZ E², CAMMUE BPA¹
¹CMPG, K.U. Leuven, Kasteelpark Arenberg, Heverlee, Belgium; ²Institut für Allgemeine Botanik, University of Hamburg, Hamburg, Germany.
- 526 Antimycobacterial and Antiplasmodial Activities of Curcuminoids and Analogues: Structure-activity Relationship Studies.
CHANGTAM C¹, THONGON N², SAENBOONRUENG J², SUKSAMRARN A¹
¹Ramkhamhaeng University, Bangkok, Thailand; ²National Center for Genetic Engineering and Biotechnology, Pathumthani, Thailand.
- 445 Eukaryotic antibiotic peptides as leishmanicidal agents. The target is not always the parasite.
RIVAS L¹, LUQUE-ORTEGA JR¹; SAUGAR JM¹, DEL SOL V², MENÉNDEZ R³, VALENZUELA C⁴, FRESNO M², MIRAS MT³, ANDREU D⁵.
¹Centro de Investigaciones Biológicas (CSIC) Madrid. ²Centro de Biología Molecular (CSIC-UAM) Madrid (Spain), ³Facultad de Veterinaria, UCM. Madrid, ⁴Instituto de Farmacología (CSIC-UCM) Madrid (Spain). ⁵Universitat Pompeu Fabra, Barcelona (Spain).
- 425 In vitro leishmanicidal activity of naphthylisoquinoline alkaloids.
Ponte-Sucre, A^{1,3}, Gronauer, T², Newman, S. ², Faber, J. ², Bringmann, G. ², Moll, H. ¹
¹Institut für Molekulare Infektionsbiologie, Universität Würzburg, Germany, ²Institut für Organische Chemie, Universität Würzburg, Germany and ³Laboratorio de Fisiología Molecular, IME, Universidad Central de Venezuela.

Category: Mechanism of tumor development and growth

10:00 AM - 12:15 PM Room assignment will be printed in the final program

- 339 TUMOR ANGIOGENESIS: KEY ROLE OF INTEGRINS.
Francesc Mitjans
Laboratorio de Bioinvestigación, Merck Farma y Química, S.A.
- 437 Cytoskeletal Actin Remodeling – A Potential Target for Cancer Therapy and Prevention.
JIANYU RAO¹
¹Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles.
- 624 Effect of circadian rhythm scrambling on toxicity and survival of tumor-bearing mice.
Alex Zvulunov,^{a,b} Leah Peleg,^{b,c} Rachel Carlebach,^b Israel E. Ashkenazi.^b
From ^aDivision of Pediatric Dermatology, Schneider's Children Medical Center, Petah-Tiqva, the ^bChronobiology Unit, Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, and ^cDanek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
- 438 Malignant Transformation of Syrian hamster embryo cells by Malachite green is Associated with Abrogation of Cell Cycle Checkpoint Controls and Increased Expression of P38 MAP Kinase.
RAO KVK, BIPASHA BOSE
Chemical Carcinogenesis Group, Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India.
- 094 Application of Expression Genomics in Predictive and Personalized Medicine: Magic Gene Expression Profiles.
CHIN KV^{1,3}, WONG YF², LIN W³
¹Susan Lehman Cullman Laboratory for Cancer Research and Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ; ²Department of Obstetrics and Gynecology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong; ³Imhoteq Co., Highland Park, NJ.
- 341 Tumor Hypoxia and Hypoxia-regulated Genes as Targets for Novel Anticancer Chemotherapy Strategies; Building on the Legacy of Paul Ehrlich and Otto Warburg.
AIRLEY RE¹, MOBASHERI A²
¹Tumor Metabolism and Therapeutics Research Group, School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, United Kingdom
²Molecular Pathogenesis and Connective Tissue Research Groups, Department of Veterinary Preclinical Sciences, University of Liverpool, Liverpool, United Kingdom.
- 550 α -Tocopheryl succinate enhances the cytotoxic effect of immunological and chemotherapeutic agents.
Tomasetti M¹, Alleva R², Benassi MS³, Neuzil J⁴, Borghi B², Procopio A¹
¹Department of Molecular Pathology and Innovative Therapies, Ancona, Italy; ²Department of Anesthesiology, Bologna, Italy; ³Laboratory of Oncology, Bologna, Italy; ⁴School of Health Sciences, Southport, Queensland, Australia.
- 222 The mechanisms of all-trans retinoic acid and arsenic trioxide-induced disease remission of acute promyelocytic leukemia.
Yongkui Jing
Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
- 641 Mechanisms of epigenetic silencing in leukemias.
M. Buschbeck, A. Gutierrez, I. Joval, L. Morey, R. Villa and L. Di Croce
Center for Genomic Regulation, Barcelona, Spain.

Category: In vitro action of antimalarials

10:45 AM - 12:30 PM Room assignment will be printed in the final program

- 061 NOVEL NATURAL ANTIMALARIALS FROM PLANTS.
BENOIT-VICAL F
¹Laboratoire de Chimie de Coordination du CNRS, ²Laboratoire de Parasitologie-Mycologie, CHU Rangueil, Toulouse Cedex, France.
- 153 Novel Options of Anti-malarials Based on Sphingolipid Metabolism and Ceramide Cytotoxic Activity.
FLESCHER E¹, PANKOVA-KHOLMYANSKY I²
¹Tel Aviv University, Tel Aviv, Israel; ²Weizmann Institute of Science, Rehovot, Israel.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 225 Critical Review of Methods for the Measurement of Antimalarial Drugs Activity.
Jouin H^{1,2}
¹Inserm U 547 Institut Pasteur, Lille, France
²Unité d'Immunologie Moléculaire des Parasites, Institut Pasteur, Paris, France.
- 458 Malaria Vectors of *Anopheles* Hyrcanus Group in Korea and Other Asian Countries: Distribution, Habitats, Morphology and Molecular Characterization.
RUEDA, L. M.¹
¹Walter Reed Biosystematics Unit, WRAIR/Smithsonian Institution, Suitland, MD, USA.
- 502 Anti-adhesive peptides and antibodies as potential therapeutics for falciparum malaria.
SHERMAN IRWIN W., WINOGRAD, ENRIQUE
University of California, Riverside, CA, USA.
- 567 Synergistic "Magic Bullet" Chemotherapy Effective Against Multiple Drug Resistant Malaria and Cancer *In Vivo*.
VAN DYKE K (1) and YE Z (2)
Biochemistry and Molecular Pharmacology, West Virginia University, Medical Center, Morgantown, WV, USA (1) and Academy of Traditional Chinese Medicine Beijing, China (2) and Cancer Biologics of America International Inc. (1).
- 591 Antimalarial Drug Resistance in *Plasmodium falciparum* – a Host of Challenges.
Wernsdorfer WH^{1,2}, Wernsdorfer G²
¹Division of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria; ²Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Category: Mechanisms of pharmacological importance

11:15 AM - 01:00 PM Room assignment will be printed in the final program

- 592 Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation.
Wetzler M
Roswell Park Cancer Institute, Buffalo, NY, USA.
- 020 Interaction of Transported Drugs with the Lipid Bilayer and P-glycoprotein: Drug Transport is Mediated by a Solvation Exchange Mechanism.
OMOTE H, **AL-SHAWI MK**
University of Virginia Health System, Charlottesville, VA, USA.
- 053 Flow cytometry for the measurement of phagocyte functions.
BASSØE C-F
Medical Department, Haukeland University Hospital, Bergen, Norway.
- 155 S100A6 and CacyBP/SIP – Two Proteins Identified in Ehrlich Ascites Tumor Cells Potentially Involved in Degradation of β -Catenin.
FILIPEK A
Nencki Institute of Experimental Biology, Warsaw, Poland.
- 141 Ploidy cycles in tumours: A reproductive pathway?
ERENPREISA JE¹, CRAGG MS², IVANOV A^{1,2}, KALEJS M¹, LIEBE B³, SCHERTHAN H³, ILLIDGE TM³
¹Latvian University Biomedical Research and Study Centre, Riga, Latvia; ²Cancer Science Division, Southampton University, United Kingdom; ³MPI for Molecular Genetics, Berlin, Germany.
- 195 Glutamine (GLN) – Magic Bullet in Treatment of Protein Wasting in Severe Illness.
HOLECEK M
Department of Physiology, Charles University School of Medicine, Hradec Kralove, Czech Republic.
- 177 Regulation of Renal Bicarbonate Transport: The Role of Sodium Bicarbonate Cotransporter – Carbonic Anhydrase Interaction.
GROSS E
Case Western Reserve University, Cleveland, OH, USA.

Category: Targeted delivery of antineoplastic agents

11:15 AM - 12:30 PM Room assignment will be printed in the final program

- 276 Prodrugs in Cancer Chemotherapy – An Overview of Active and Passive Targeting Strategies.
KRATZ F
Tumor Biology Center, Freiburg, Germany.
- 243 Lipidic carriers of siRNA: differences in the formulation, cellular uptake and delivery with plasmid DNA.
Sebastien Spagnou, Andrew D. Miller and **Michael Keller**
IC-VEC Ltd, London, UK.
- 151 Nanoparticles of Biodegradable Polymers for Cancer Chemotherapy.
FENG SS
Department of Chemical & Biomolecular Engineering and Department of Bioengineering, National University of Singapore.
- 180 Superparamagnetic Iron Oxide Nanoparticles as Magic Bullets for Cell Targeting.
GUPTA AK¹, **GUPTA M²**
¹Crusade Laboratories Limited, Southern General Hospital, Glasgow, U.K.; ²Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, U.K.
- 018 Targeted Therapeutics in the Treatment of Cancer.
ALLEN, TM¹, **PONZONI, M²**, **PASTORINO, F²**, **SAPRA, P¹**
¹Pharmacology, Univ. Alberta, Edmonton, Canada; ²G. Gaslini Children's Hospital, Genoa, Italy.

Category: Analytical techniques

12:30 - 01:45 PM Room assignment will be printed in the final program

- The use of capillary electrophoresis to determine counterfeit antibiotics.
HOLZGRABE U
Institute of Pharmacy and Food Chemistry, University of Wuerzburg, Germany.
- 640 IMMUNOAFFINITY CAPILLARY ELECTROPHORESIS AS A TOOL FOR EARLY DIAGNOSIS OF SEPTIC SHOCK AND AS A POTENTIAL SCREENING TEST IN ITS PROGNOSIS.
Norberto A. Guzman
Bioanalytical Drug Metabolism, Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA.
- 226 Use of Enzyme Linked Immunosorbent Assay (ELISA) for the Diagnosis of Clinically Suspected Referred Human Cystic and Alveolar Hydatidosis Cases in Nepal.
D.D. Joshi, Mahendra Maharjan, Harish Joshi, P.B. Chand
National Zoonoses & Food Hygiene Research Centre (NZFHRC), Chagal, Kathmandu, Nepal.
- 604 Detection of Leptospira Agglutination by using Flow-Cytometry Light Scatter Analysis: A New Approach for Serological Testing for Leptospirosis.
YITZHAKI S¹, **ZAHAVY E¹**, **BARNEA A¹**, **KEYSARY¹ A**
Israel Institute for Biological Research Ness-Ziona, Israel.

Category: Role of cells and their staining by dyes

12:40 - 02:35 PM Room assignment will be printed in the final program

- 311 Location, Orientation and Dynamics of Fluorescent Dyes in Lipid Bilayer Membranes.
Krishna MMG^{1,2}, **Periasamy N¹**
¹Tata Institute of Fundamental Research, Mumbai, India; ²University of Pennsylvania School of Medicine, Philadelphia, USA.
- 296 Differential Cytoprotective Activity of Carboxyfullerene.
LIN H-S¹, **LIN T-S¹**, **D'ROSARIO T¹**, **LUH T-Y²**
¹Washington University, St. Louis, MO, USA, ² National Taiwan University, Taipei, Taiwan.
- 559 The clinical and therapeutic relevance of cytokeratin immunostaining of metastatic adenocarcinomas.
Tot T
Department of Pathology and Clinical Cytology, Central Hospital, Falun, Sweden.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 348 The Role of the Eosinophil in Health and Disease.
**¹Moqbel R., ¹Odemuyiwa S.O., ²Adamko D., ³Ghahary A.
Departments of Medicine¹, Pediatrics² and Surgery³, University of Alberta, Edmonton, Alberta, CANADA.**
- 566 Mast cells and mastocytosis: From Paul Ehrlich to the current millennium.
Peter Valent
Department of Internal Medicine I
Division of Hematology & Hemostaseology
Medical University of Vienna, Austria.
- 600 Using microencapsulated iNOS-expressing cells as an 'artificial macrophage' to combat the infectious microbes and cancer.
WEIMING XU & LIZHI LIU
Wolfson Institute for Biomedical Research, University College London.
- 588 Mitochondria-Targeted Bolasomes as "Magic Bullets" on the Subcellular Level.
WEISSIG V
Northeastern University, Bouve College of Health Sciences, School of Pharmacy, Department of Pharmaceutical Sciences, Boston, MA, USA 340.

Category: Antineoplastic agents - new and known synthetic compounds

12:45 - 02:30 PM

Room assignment will be printed in the final program

- 415 More bullets against carcinomas: MUC1 epitopes, Flt3 ligand (Flt3L) and Pluronic block copolymers (PBC).
PISAREV VM¹, KINARSKY L¹, CAFFREY T¹, HANISCH F-G², von MENS DORF-POUILLY S³, KABANOV A, Hollingsworth MA¹, SHERMAN S¹
¹Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; ²Institute of Biochemistry, Medical faculty, and Central Bioanalytics of the Center of Molecular Medicine, University of Cologne, Germany; Dept. of Obstetrics and Gynaecology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
- 186 Molecular Mechanism of Antitumour Effect of Diospyrin and Derivatives.
HAZRA B¹, DAS SARMA M¹, KUMAR B¹, DAS K¹, PANDEY BN², MISHRA KP²
¹Jadavpur University, Calcutta, India; ²Bhabha Atomic Research Centre, Mumbai, India.
- 203 Drug Design of BPR0L075 as an Anti-Cancer Agent.
Hsing-Pang Hsieh¹; Jing-Ping Liou¹; Chun-Wei Chang¹; Ching-Chuan Kuo²; Yi-Ling Chang¹; Fu-Ming Kuo¹; Huan-Yi Tseng¹; Wen-Yu Pan²; Ching-Ping Chen¹; Yung-Ning Yang¹; Chiung-Tong Chen¹; Shioh-Ju Lee¹; Jang-Yang Chang²
¹Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, Taiwan; ²Divisions of Cancer Research, National Health Research Institutes, Taipei, Taiwan.
- 337 Oxazaphosphorinane Drugs. New Analogues and Metabolic Studies and New Therapeutic Approaches.
Konrad Misiura
Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland.
- 614 Benefit of liposomes prepared from alkylphospholipids for the treatment of cancer.
ZEISIG R, WALTHER W, FICHTNER, I.
Max Delbrück Center for Molecular Medicine Berlin-Buch, Germany.
- 172 The X_c⁻ Cystine/Glutamate Antiporter as an Anticancer Target - Evaluation of the Azocompound, Sulfasalazine (SASP).
GOUT PW, WANG YZ
BC Cancer Agency, Vancouver, Canada.
- 630 Amonafide: Past, Present and Future.
Braña MF1
Universidad San Pablo-CEU, Madrid, Spain.

Category: Targeted delivery of antineoplastic agents

12:45 - 02:20 PM

Room assignment will be printed in the final program

- Pharmacokinetics of high-molecular anticancer agents
Kloft C
Freie Universitaet Berlin, Institute of Pharmacy, Berlin, Germany.
- 284 Targeted drug delivery via reconstituted high density lipoproteins (rHDL).
LACKO AG, NAIR, M. PARANJAPE S, MOOBERRY L, McCONATHY, WJ
University of North Texas Health Science Center, Fort Worth, TX.

- 494 The Use of Modified Forms of the EGF Receptor Binding Fragment for Targeted Drug Delivery to Cancer Cells.
SEVERIN S.E., FELDMAN N.B., LUTSENKO S.V
Research Institute of Medical Ecology, Moscow, Russia.
- 510 Targeted Delivery of Chemotherapy Drugs via a Prostate Specific Antibody Induces Apoptosis and Inhibits Cell Proliferation in Human Prostate Cancer Cells *in vitro* and Their Tumors in Nude Mice.
SINHA AA^{1,2,4}, WILSON MJ^{2,3,4}, REDDY PK², PRETLOW TG⁵
¹Depts. of Genetics, Cell Biol. & Develop., ²VA Research Service, ³Lab. Med. & Pathol., ⁴Cancer Center, Univ. of Minnesota, Minneapolis, MN, and ⁵Institute of Pathol., Case Western Reserve Univ., Cleveland, Ohio, USA.
- 132 Microdosimetry and Intratumoral Localization of Intravenously Administered ¹³¹I Labelled Monoclonal Antibodies (mAb) are critical to successful Radioimmunotherapy (RIT) of lymphoma.
DU Y, JOHNSON P, GLENNIE M, ILLIDGE T
Cancer Sciences Division, University of Southampton, UK.
- 164 Identification of Target Genes in Oncology – The Genomic Approach.
GEBAUER G (1+2), KRONES-HERZIG A (2), GLINSKY G (2), MCCLELLAND M(2)
(1) Department of Cell and Molecular Biology, Sidney Kimmel Cancer Center, San Diego, CA, USA; (2) Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.

Category: Antimalarial compounds - clinical studies

01:30 - 03:00 PM Room assignment will be printed in the final program

- 108 Double-blind randomised controlled trial of malaria chemoprophylaxis in British soldiers, with extended follow-up.
Croft AM, von Bertele MJ, Brutus EC
Headquarters British Forces Germany Health Service, Mönchengladbach, Germany.
- 265 Relationship of Parasite Count Dropping Rate and Clinical Outcome in Severe Falciparum Malaria.
K H KOH, P H CHEW.
Sarawak General Hospital, Malaysia.
- 264 Hepatic dysfunction and hepatic encephalopathy in malaria.
KOCHAR DK, AGARWAL P, KOCHAR SK, JAIN R, RAWAT N, POKHARNA RK, KACHHAWA S, SRIVASTAVA T
S.P. Medical College, Bikaner – India.
- 637 Malaria Control Trials by Transmission Blocking with Primaquine.
ISHII A
Jichi Medical School, Tochigi, Japan.
- 227 Toxicity of Antimalarial Drugs: A review.
HUSSIEN O. ALKADI
Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.
- 434 Malaria Control – Prospects.
Raghunath, D.
Sir Dorabji Tata Centre for Research in Tropical Diseases Innovation Centre, Indian Institute of Science Campus, Bangalore.

Category: Adverse events, interactions and toxicity of antiinfectives

02:30 - 04:30 PM Room assignment will be printed in the final program

- 293 DRUG INDUCED APLASTIC ANEMIA, REVIEW.
Micha Levy
Hebrew University Jerusalem, Israel.
- 065 Dose-Effects of Fluoroquinolones (FQs) on Intestinal Penetration, Hepatic Isoforms and DNA Damage in Rat.
BERTAZZONI MINELLI E, BENINI A, DORIA D, FRANCESCHETTI P, and FRACASSO M E
Dpt. Medicine and Public Health, Pharmacology Section, University of Verona, Verona, Italy.
- 001 Cefepime-induced Neurotoxicity: A Retrospective Review With a Proposed Mechanism.
ABANADES S¹, NOLLA J², RODRÍGUEZ-CAMPELLO A³, ROSET PN¹, FARRE M¹
¹Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain
²Hospital Universitari del Mar, Universitat Pompeu Fabra, Barcelona, Spain

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- ³Hospital Universitari del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
- 246 Impaired Cognition as a Sensitive Index of Antibiotics' Behavioral Toxicity: A Review.
Khalifa AE
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
- 049 Interactions of Antiinfectives: A Review.
BARCIA E, NEGRO S
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Spain.
- 217 An Overview of Life-Threatening Interaction of Macrolides with Cardiovascular Drugs.
JAMALI F AND DAKHEL Y
Faculty of Pharmacy & pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
- 423 Interactions of Antiinfectives.
PONTALI E
Health services – Prison of Genoa; Genoa, Italy.
- 619 Enzyme Kinetics for Cytochrome P450 (CYP) Inhibition in Antiretroviral Therapy.
ZHI-YI ZHANG, NANCY Y WONG
Drug Safety and Disposition, Eisai Research Institute, Andover, MA, USA.

Category: Antineoplastic agents - new and known non-synthetic compounds & Antineoplastic agents - clinical studies

02:45 - 05:00 PM

Room assignment will be printed in the final program

- 340 Alpha-fetoprotein Growth Inhibitory Peptide as an Antineoplastic Therapeutic Agent: The Use of Peptides as Targeted Magic Bullets in *In Vitro* and *In Vivo* Models.
MUEHLEMANN M, MIZEJEWSKI GJ
Serometrix LLC, Syracuse, NY, USA.
- 489 MTC 170 – A novel endogenous magic bullet against cancer.
Schwamberger G¹, Freudenberg M², Galanos C²
¹ Dept. of Molecular Biology, University of Salzburg, Austria
² Max-Planck-Institute for Immunobiology, Freiburg, Germany.
- 133 Overview of Violacein Biological Activities: Biochemical Aspects of Its Cytotoxicity and Strategies to Improve Its Effectiveness.
DURÁN N^{1,2}, JUSTO GZ³, BROMBERG N¹, MELO PS³, HAUN M³, FERREIRA CV³, DE MELLO MP⁴, BINCOLETTO C², DE SOUZA AO⁵, DE AZEVEDO MMM¹, DE AZEVEDO MBM¹, LEON LL⁶, DE CASTRO SL⁶
¹Instituto de Química, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil; ²Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil; ³Instituto de Biologia, UNICAMP; ⁴CBMEG, UNICAMP; ⁵USP-RP, Ribeirão Preto, SP, Brazil; ⁶FIOCRUZ, Rio de Janeiro, RJ, Brazil.
- 332 Effects of indole phytoalexins on growth of cancer cells.
MEZENECV R¹, PILATOVA M¹, MOJZIS J¹, KUTSCHY P²
¹Medical Faculty PJ Safarik University, Kosice, Slovakia; ²Faculty of Science PJ Safarik University, Kosice, Slovakia.
- 470 Promotion of targeted anticancer apoptosis: a natural "magic bullet".
SALGANIK RI, ALBRIGHT CD, VAN DYKE TA
The University of North Carolina, Chapel Hill, NC, USA.
- 610 Anticarcinogenic Effects of *Panax ginseng* C.A. Meyer and Identification of Active Compounds, Including Enzymatically Producing Ginsenosides Rh₂, Rg₃ and Rg₅ from Red Ginseng.
YUN T-K
Korea Institute for Cancer Chemoprevention, Seoul, Korea.
- 541 Stromal targeted therapy: will manipulation of the haemopoietic microenvironment improve outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML)?
S Tauro
University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UK.
- 513 Phase I/II study of adenovirus-interferon- γ (TG1042) in primary cutaneous lymphomas (CL).
Slos P*, Urosevic M, Bleuzen P*, Bataille V*, Burg G, Squiban P*, Dummer R
University Hospital Zurich, Switzerland. *Transgene, Strasbourg, France.

- 570 The independent prognostic effect of co-morbidity in lymphoma patients: results from the population-based Eindhoven Cancer Registry.
D.J. VAN SPRONSEN¹ (1), M.L.G. JANSSEN-HEIJNEN², V.E.P.P. LEMMENS², W.G. PETERS³, J.W.W. Coebergh²
¹Department of Medical Oncology, UMC St Radboud, Nijmegen, The Netherlands
²Comprehensive Cancer Centre South, Eindhoven, The Netherlands
³Department of Internal Medicine, Catharina Hospital Eindhoven, The Netherlands.

Category: Clinical studies and use of antibiotics

02:45 - 05:15 PM Room assignment will be printed in the final program

- 102 Azythromycin versus doxycycline treatment in early Lyme borreliosis: Clinical outcome and antibody response.
CHRISTOVA I
National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
- 345 Cerebral Blood Flow, Metabolism and Flux in Patients with Acute Bacterial Meningitis (REVIEW).
MØLLER K
Department of Infectious Diseases, University Hospital Rigshospitalet, Copenhagen, Denmark.
- 515 The Importance of Combating Plaque Biofilm for Oral and Systemic Health.
SOORY M
GKT Dental Institute, King's College London, UK.
- 549 Moxifloxacin as an Alternative Antimicrobial Prophylaxis of Bacteraemia Following Dental Procedures.
TOMÁS I¹, LIMERES J¹, ALVAREZ M², LÓPEZ-MELÉNDEZ C², MEDINA J³, DIZ P¹.
1-Santiago de C. University, Spain; 2-Xeral-Cies Hospital, Vigo, Spain; 3-CHUS, Santiago de C., Spain.
- 522 An Overview of Skin Infections and Application of Non-invasive Methods for the Evaluation of the Skin Condition.
STAMATAS GN, KOLLIAS N
Johnson & Johnson, Skillman, New Jersey, USA.
- 524 The Potential Risk of Erythromycin as Empiric Therapy for Therapy Failure in Acute Respiratory Tract Infections.
NYS S¹, TJHIE JHT², SPEE K¹, BARTELDs AIM³, HEIJNEN MLA⁴, PEETERS MF⁵,
STOBBERINGH EE¹
¹University Hospital Maastricht, Maastricht; ²PAMM Laboratory, Veldhoven; ³Nederlands Instituut voor Onderzoek in de Gezondheid (NIVEL), Utrecht; ⁴Centrum voor infectieziekten en Epidemiologie (RIVM), Bilthoven; and ⁵Streeklaboratorium voor Volksgezondheid, Tilburg, The Netherlands.
- 419 Treatment of Streptococcus pneumoniae Bacteremia (SpB). Are Two Drugs Better than One?
Plouffe JF¹, Martin D¹
¹University Hospital, Columbus, OH, USA.
- 204 Penicillin Remains the First Drug of Choice for the Treatment of Pneumococcal Pneumonia in Taiwan with High Rate of Penicillin Resistance in *Streptococcus pneumoniae*.
HSUEH PR¹, HUANG WK², TENG LJ¹, SHYR JM³, LIU YC²
¹National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei; ²Kaoshiung Veterans General Hospital, Kaoshiung; ³Taichung Veterans General Hospital, Taichung, Taiwan.
- 017 Determining the clinical utility of the urine pneumococcal antigen in the diagnosis and empiric management of community acquired pneumonia.
Zakari Y. Aliyu, DA Colvin, HM Salihu, DK Walshe, S Ondiek
St. Agnes Hospital, Baltimore Maryland.
- 135 Thyroid Tuberculosis: Diagnosis and Treatment about 8 cases.
EL MALKI H O¹, BENJELLOUN H², AMAHZOUNE M¹, MOHSINE R¹, CHEFCHAOUNI M C¹, OULBACHA S¹, IFRINE L¹, BELKOUCHI A¹, BALAFREJ S¹.
¹Clinique chirurgicale "A" Hôpital Ibn Sina, faculté de médecine et de pharmacie Rabat-Morocco
²Cardiologie "A" Hôpital Ibn Sina, faculté de médecine et de pharmacie Rabat-Morocco.

Category: Clinical studies and use of antibiotics

03:15 - 04:45 PM Room assignment will be printed in the final program

- 633 The Future of Premature Infants During Paul Ehrlich's Time.
GOLOMBEK SG¹
¹The Regional Neonatal Center, Westchester Medical Center/New York Medical College, Valhalla, New York, USA.
- 586 Another Kind of Magic Bullet.
WARWICK WJ
Minnesota Cystic Fibrosis Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
- 240 Pediatric Febrile Neutropenia: 14 Years Experience.
R KEBUDİ¹, İ AYAN¹, Ö GÖRGÜN¹, N GÜRLER²
İstanbul University, ¹Oncology Institute, Division of Pediatric Oncology, ²Department of Microbiology, İstanbul, Turkey.
- 157 Is Prophylactic Administration of Antimicrobial Agents to Surgical Patients a Safe Procedure? The anesthesiologist's point of view.
FODALE V, PRATICO C, LUCANTO T, SANTAMARIA LB.
University Hospital, Messina, Italy.
- 279 Atypical Features of Leptospirosis – A Study at Pondicherry, India.
DUTTA TK, CHRISTOPHER MA, AHMED SM, KANUNGO R, DAS AK
Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India.
- 013 Failure of a Short-Term Antibiotic Therapy for Human Brucellosis – What is Currently the State of the Art?
AL DAHOUK S¹, NÖCKLER K², TOMASO H¹, HAGEN RM¹, WITTIG M¹, SCHOLZ HC¹, NEUBAUER H¹
¹Bundeswehr Institute of Microbiology, Munich, Germany, ²Federal Institute for Risk Assessment, Berlin, Germany.

Saturday, September 11, 2004

Category: Microbiology & Resistance to antiinfectives

07:30 - 09:30 AM Room assignment will be printed in the final program

- 270 Anaerobes and Production of β -Lactamases in the Upper Respiratory Tract in Early Childhood.
KÖNÖNEN E
National Public Health Institute (KTL), Helsinki, Finland.
- 605 Antibacterial Activities of Antibiotic Bonded/Impregnated Catheters.
YORGANCI K¹, KREPEL C², WEIGELT JA³, EDMISTON CE²
¹Hacettepe University, Faculty of Medicine, Dept. of Surgery, Ankara, Turkey, Medical College of Wisconsin, ²Surgical Research Lab. and ³Dept. of Surgery, Milwaukee, Wisconsin, USA.
- 041 Antibiotics inhibiting the ribosome: structure and function.
¹AUERBACH T, ¹BARAM D, ¹ZARIVACH R, ¹SITTNER A, ¹BASHAN A, ^{1,2}PYETAN E, ²SCHLUENZEN F, ²HARMS J, ²BERISIO R AND ^{1,2}YONATH A
¹Weizmann Institute of Science, Rehovot, Israel, ²Max-Planck Research Unit for Ribosomal Structure, Hamburg.
- 418 Phenotypic Resistance: The Next Battleground in Treatment Effectiveness.
PLOTKIN BJ¹, KONAKLIEVA MI²
Midwestern University, Downers Grove Illinois, U.S.A.; American University, Washington, D.C., U.S.A.
- 070 Application of the Resistance Prevention Concentration (RPC) & Minimal Inhibitory Concentration (MIC) of Clinical Isolates of *Streptococcus pneumoniae* (SP) Against Macrolides.
BLONDEAU JM^{1,2}, BORSOS S¹
¹Royal University Hospital, Saskatoon, SK, Canada, ²University of Saskatchewan, Saskatoon, Canada.
- 206 Physiological costs of antibiotic resistance.
Hughes D, Macvanin M, Komp Lindgren P, Marcusson LL, Norström T
Department of Cell and Molecular Biology, Microbiology Programme, Box 596 BMC, Uppsala University, Uppsala, Sweden.

- 266 Efflux Mediated Antibiotic Resistance in Clinical Isolates of *Pseudomonas aeruginosa*.
T. Köhler
Dept. of Microbiology and Molecular Medicine, University of Geneva, Switzerland.
- 306 Antibacterial Photodynamic Inactivation of Multi-resistant *Staphylococci* Strains.
MAISCH T¹, BOSL C¹, SZEIMIES R-M¹, LOVE B², ABELS C¹
¹University Hospital of Regensburg, Germany, ²Destiny Pharma, Brighton, UK.

Category: Antiviral agents

07:30 - 10:00 AM

Room assignment will be printed in the final program

- 414 Interferon; between magic bullet and panacea.
Toine Pieters
VU-Amsterdam Medical Centre, Department Metamedica, Amsterdam, The Netherlands.
- 466 Expression of Suppressor of Cytokine Signaling 3 (SOCS3) in Bone Marrow Cells from Chronic Myelogenous Leukemia (CML) Patients associated with Cytogenetic Response to Interferon-alpha (IFN- α).
SAKAI I¹, TAKEUCHI K¹, NARUMI H¹, YASUKAWA M¹, FUJITA S¹
¹Ehime University School of Medicine, Sigenobu, Japan.
- 033 Elucidation of a Novel Molecular Mechanism by which Influenza Develops Resistance Against Amantadine, the M2 Channel Blocker.
ASTRAHAN P¹, KASS I¹, COOPER MA², **ARKIN IT¹**
¹Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel; ²Akubio Limited Cambridge, UK.
- 377 Antagonistic Combined Effects of Ribavirin and Some Picornavirus Replication Inhibitors.
Nikolaeva-Glomb, L and Galabov, A S
The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences.
- 540 Meclofenoxate (Centrophenoquine, Acephen, etc.) can inhibit the retrovirus budding on the plasma membrane of lymphoid line cells.
Tatariunas A.
Kaunas Medical University, Lithuania.
- 560 Antiretroviral compounds interfere with cytotoxic T lymphocytes functions.
TRABATTONI D¹, PICONI S¹, BIASIN M¹, SCHENAL M¹, RUSCONI S⁴, CLERICI M¹
¹Chair of Immunology, DISP LITA VIALBA, and ²Infectious Diseases Clinic, University of Milano, Italy.
- 573 Biologic Properties of Structurally Modified β -Lactams Acting as Protease Inhibitors.
VEINBERG G, VORONA M, SHESTAKOVA I, KANEPE I, LUKEVICS E
Latvian Institute of Organic Synthesis, Riga, Latvia.
- 107 The stable cyclotide framework for the delivery of therapeutic peptides: anti-HIV activity of kalata B1.
CRAIK DJ¹, COLGRAVE ML¹, DALY NL¹, GUSTAFSON KR²
¹Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. ²Molecular Targets Development Program, National Cancer Institute, Frederick, USA.
- 421 Comparative Molecular Surface Analysis (CoMSA): Application for Diketoacid (DKA) Pharmacophore Mapping in HIV Integrase Inhibitors.
J. Polanski¹, H. Niedbala¹, R. Musiol¹, B. Podeszwa¹, D. Tabak¹, A. Palka, J.-F. Mouscadet², R. Gieleciak¹, A. Bak¹, T. Magdziarz, J. Gasteiger³, M. Le Bret²
¹Department of Organic Chemistry, University of Silesia, Katowice, Poland, ²CNRS UMR 8532, LBPA, Ecole Normale Supérieure de Cachan, Cachan, France, ³Computer-Chemie-Centrum, Institute of Organic Chemistry, University of Erlangen-Nürnberg, Erlangen, Germany.
- 565 A primary macrophage model – a simple approach to study the effect of antiviral agents as well as host susceptibility to flavivirus West Nile.
PANTELIC L, UROSEVIC N
Microbiology, School of Biomedical and Chemical Sciences, The University of Western Australia, Nedlands/Perth, Australia.

Category: Mechanisms of pharmacological importance

08:00 - 09:45 AM Room assignment will be printed in the final program

- 239 Biochemical Characterization of the Doxorubicin Transporter from *Streptomyces peuceetius*.
KAUR P and GANDLUR SM
Department of Biology, Georgia State University, Atlanta, Georgia, USA.
- 221 The Antinociceptive response of *Buthus martensi* Karsch (BmK) AS, a Na channel Receptor Site 4 Modulator, and its possible underlying mechanism.
JIN CHEN¹, XING-HUA FENG¹, JIAN SHI¹, ZHI-YONG TAN², **YONG-HUA JI**^{1CA}
¹The Key Laboratory of Neurobiology, Institute of Physiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai P.R. China; ²Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut, USA.
- 275 Fluorescence Correlation Spectroscopy: a new tool for characterizing DNA plasmid condensation.
KRAL T^{1,2}, LANGNER M^{3,4}, HOF M¹
¹J. Heyrovský Institute, CAS and Center for Complex Molecular Systems and Biomolecules, Prague, Czech Republic, ²Agricultural University, Wrocław, Poland, ³Wrocław University of Technology, Wrocław, Poland, ⁵Academic Centre for Biotechnology of Lipids Aggregates, Wrocław, Poland.
- 302 Fibroblastic Cells from Human Periapical Granulation Tissue (HFC) Preferentially Form Calcified Matrices in Rat Decalcified and Boiled Bone (DBB).
MAEDA H¹, WADA N¹, FUJII S¹, NODA R¹, AKAMINE A¹
¹Kyushu University, Fukuoka, Japan.
- 325 The c-kit mutation D816V induces differentiation and cluster formation in Ba/F3 cells and predicts the pathology and clinical course of indolent systemic mastocytosis.
Matthias Mayerhofer, Peter Valent
University of Vienna, Austria.
- 357 Relevance Of Surface Activity And Liquid Membrane Phenomena In Tissue Penetration And Drug Absorption.
Nagappa AN¹
Pharmacy Group, Birla Institute of Technology and Science, Pilani, India.
- 373 Hypericin Derivative as a Magic Bullet for in vivo Targeting Hepatic and Cardiac Infarction.
NI Y¹, BORMANS G², CHEN F¹, FONGE H², VERBRUGGEN A², MARCHAL G¹.
Departments of Radiology¹ and Radiopharmaceutics², University Hospital Gasthuisberg, K.U. Leuven, Belgium.

Category: Clinical studies and use of antibiotics

08:15 - 09:30 AM Room assignment will be printed in the final program

- 346 Prophylaxis of the Systemic Inflammatory Response Syndrome (SIRS) with N-acetylcysteine treatment: a Magic Bullet or a Fraud?
MOLNAR Z
University of Pécs, Pécs, Hungary.
- 589 A holistic approach to MRSA-eradication using intravenous linezolid/rifampicin, intratracheal vancomycin, nasal mupirocin, cutaneous and enoral chlorhexidin plus povidone-iodine in critical ill patients with MRSA-pneumonia.
Wenisch C¹, Krause R¹
¹Infectious Diseases and Intensive Care, Medical University Graz, Austria.
- 315 The influence of local infusion of fusidic acid in the development of septic complications after lung resections.
MARKOGIANNAKIS A¹, SFYRIDIS P², BALTAYIANNIS N², TSAKRIS A¹, HATZIMICHALIS A²
¹Faculty of Nursing, University of Athens, Greece; ²Metaxa Cancer Hospital, Piraeus, Greece.
- 072 Infectious Complications in Hematopoietic Stem Cell Transplant Recipients: Experience at Pisa General Hospital.
M. Bonadio, G. Morelli, S. Mori, R. Riccioni, E. Tagliaferri, M. Petrini
Section of Infectious Diseases and Hematology Unit, University - Hospital, Pisa, Italy.
- 173 Six Years Experience of Using Meropenem & Vancomycin in First-line Empiric Antimicrobial Regimens in Paediatric Haematology & Oncology (PHO).
GRAY JW
Birmingham Children's Hospital (BCH), UK.

Category: About mechanisms and Magic Bullets

09:45 - 12:00 PM Room assignment will be printed in the final program

- 486 Magic Bullets and Lectins Reunited – Ehrlich's Contribution to Lectinology.
Schumacher U¹, Mewe M¹, Thies A¹, Schneppenheim R², Pfüller U³, Tielker D⁴, Jäger KE⁴
¹Experimental Morphology, Hamburg, ²Pediatric Oncology, Hamburg, ³Phytochemistry, Witten-Herdecke, ⁴Forschungszentrum Jülich.
- 004 Treatment of Glucosphingolipid Storage Disorders with Novel Inhibitors of Glucosylceramide Synthase.
ABE A¹, WILD S¹, LEE L¹, SHAYMAN JA¹
¹University of Michigan, Ann Arbor, MI, USA.
- 022 How Does *Rhodococcus opacus* Adapt to Environmental Stresses?
ALVAREZ HM, SILVA RA, ALVAREZ AF, BARRÍA M
Departamento de Bioquímica, Facultad de Ciencias Naturales, Universidad Nacional de la Patagonia San Juan Bosco, Comodoro Rivadavia, Chubut, Argentina.
- 435 Ehrlich's "magic bullet" and current situation with infectious diseases.
SMITHYMAN AM¹, **RAJASEKARIAH GR**¹
¹Cellabs Pty Ltd, Dale St, Brookvale, NSW, Australia.
- 046 FROM "BLUTGIFT" TO BIO - WEAPON: RICIN - 2004.
BALINT GA
Laboratory of Clinical Pharmacology, Dept. of Psychiatry; New Clinics; University of Szeged Medical School, SZEGED, HUNGARY.
- 310 SINGLE AGENT ONE DOSE THERAPY VERSUS MULTIPLE AGENT POLYTHERAPY FOR PROPHYLAXIS IN MINILAPAROTOMY HYSTERECTOMY: OUR EXPERIENCE.
MONIKA MALHOTRA, JB SHARMA, R.ARORA, S BATRA
Department of Obstetrics and Gynaecology, Maulana Azad Medical College, New Delhi, India.
- 455 Perilymph time-concentration profile of guinea pig cochlea after systemic and local application of caroverine.
CHEN Zhiqiang^{a,b}, **DUAN Maoli**^b, **RUAN Runsheng**^{a,c}, **ULFENDAHL Mats**^b
^aDepartment of Otolaryngology, National University of Singapore, Lower Kent Ridge Road, Singapore
^bDepartment of Clinical Neuroscience and Center for Hearing and Communication Research, Karolinska Institutet, Stockholm, Sweden
^cInstitute of Bioengineering and Nanotechnology, The Nanos, Singapore.
- 631 The Era of Targeted Therapies in Cancer.
Miguel H. Bronchud
Clinical Oncology, Hospital General of Granollers Barcelona- Spain.
- 646 Chaos, Cancer and The Cellular Operating System.
JONES AS, TAKTAK A, FISHER A and HELLIWELL T
The University of Liverpool, Faculty of Medicine.

Category: Blood brain barrier

10:00 - 11:00 AM Room assignment will be printed in the final program

- 008 Applications of a Blood-Brain Barrier Technology Platform to predict CNS penetration of drugs in various series of therapeutics families. I. Computational Model.
ADENOT M¹, PERRIERE N^{1,2}, SCHERMANN JM², LAHANA R¹
¹Synt:em, Nîmes, France; ²INSERM U26, Hôpital F.Widal, France
- 283 Neuroinflammation results in opening blood-brain barrier/BBB/ for peripheral peptides.
KWIATKOWSKA-PATZER B, KLINOWIECKA A, KOSSON P, WALSKI M, FRONTCZAK-BANIEWICZ M, LIPKOWSKI AW
Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
- 420 Pathological Opening of the Blood-Brain Barrier (BBB) to Horseradish Peroxidase (HP) and Amyloid Precursor Protein (APP) Following Ischemia-Reperfusion Brain Injury.
PLUTA R^{1,2}
¹Medical Research Centre, Warsaw; ²Pedagogical University, Częstochowa, Poland.
- 076 MANIPULATING THE BLOOD BRAIN BARRIER FOR STEM CELL THERAPY IN STROKE
Cesar V Borlongan^{1,2,3*}, Cyndy D Davis⁴, Paul R Sanberg⁴, ¹Dept Neurology, ²Inst Molecular Medicine and Genetics, Medical College of Georgia; ³Augusta VAMC, Augusta GA 30912; ⁴Center of Excellence for Aging and Brain Repair, University of South Florida College of Medicine, Tampa FL.

Category: Mechanisms of action of antineoplastic agents including resistance

10:10 - 11:40 AM Room assignment will be printed in the final program

- 297 An ATP-Dependent Switch Controls the Transport Cycle of the Multidrug Resistance P-Glycoprotein.
LINTON KJ¹, ZOLNERCIKS JK¹, WOODING C¹, KERR ID² and HIGGINS CF¹.
¹MRC Clinical Sciences Centre, London, UK. ²University of Nottingham, Nottingham, UK.
- 099 Development Of a Novel Resistance Modifying Agent To Overcome Multidrug Resistance In Cancer.
S K CHOUDHURI, P DUTTA, S MAJUMDER and A MOOKHERJEE
Department of Environmental Carcinogenesis and Toxicology Chittaranjan National Cancer Institute, Calcutta, INDIA.
- 193 Multidrug Resistance Gene (*MDR1*) Polymorphism G1199A alters P-Glycoprotein Efflux Activity and Drug Resistance (new data).
WOODAHL EL, YANG Z, BUI T, SHEN DD, **HO RJY**
University of Washington, Seattle, WA, USA.
- 463 Possible Molecular and Cellular Action Mechanisms of Catechins Explaining the Beneficial Effects of catechins on the Development of Cancer Diseases.
AGAPIO SACHINIDIS
Center of Physiology and Pathophysiology, Institute of Neurophysiology, Cologne, Germany.
- 625 Molecular mechanisms for the repair of DNA damage induced by anticancer topoisomerase inhibitors.
ADACHI N, IIZUMI S, SO S, KOYAMA H
Kihara Institute for Biological Research, Yokohama City University, Yokohama, Japan.
- 608 Magic bullet for breast cancer prevention: To prevent the formation of estrogen epoxide.
Yu FL
Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, USA.

Category: Agents involving the immune system

11:15 AM - 01:00 PM Room assignment will be printed in the final program

- 299 From the Magic Bullet to a Better Fort - Up Regulation of Host Immunity.
LORIA RM.
Virginia Commonwealth University, Medical Center, Dep of Microbiology, Immunology, Pathology and Emergency Medicine, Richmond Va. USA.
- 300 Magic Bullets for Cancer Drugs and Cancer Gene Therapy.
LUNDSTROM K
Regulon Inc./Cancer Therapeutic Sciences, Epalinges (Lausanne) Switzerland.
- 403 Magic bullets – magic ghosts: targeting of colon cancer cells and macrophages by bacterial ghosts loaded with doxorubicin.
PAUKNER S.^{1,2}, KOHL G.² AND LUBITZ W.^{1,2}
¹Institute for Microbiology and Genetics, Vienna Biocenter, University of Vienna, Austria
²BIRD-C GmbH & Co KEG, Vienna, Austria
- 433 Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties.
QUEIROZ MLS¹, VALADARES MC¹, BINCOLETTO C^{1,2}
¹Departamento de Farmacologia/Hemocentro, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil; ²Centro Interdisciplinar de Investigações Bioquímicas, Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil.
- 578 Immunologically Specific Activation of Anticancer Prodrugs by Monoclonal Antibody β -Lactamase Conjugates.
VRUDHULA VM, KERR DE, SIEMERS NO, SVENSSON HP, WALLACE PM, SENTER PD
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, U.S.A.
- 603 Identification of a small molecule organic compound for prevention of complement-mediated immune hemolysis.
YAZDANBAKSH K¹, MQADMI M¹, ZHENG X¹, SONG J¹, ABRAMOWITZ S¹, GICLAS P²
¹Complement Biology, New York Blood Center, New York, USA.
²Complement Laboratory, Pediatrics Dept, National Jewish Medical and Research Center, Denver, USA.

World Conference on Magic Bullets
Celebrating Paul Ehrlich's 150th Birthday
Nürnberg, Germany, September 9-11, 2004

- 623 Knockdown of PU.1 by siRNA on CD34⁺ Hematopoietic Stem Cells Derived from Mouse Embryonic Stem Cells Turns Cell Fate Determination to pro-B Cells.
ZOU GM^{1,2}, CHEN JJ¹, WU W¹, ROWLEY JD¹
¹Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center; USA. ²Current address: Herman B Well Center for Pediatrics Research, Indiana University School of Medicine.

Category: Design of drug delivery & Vaccination

12:15 - 01:15 PM Room assignment will be printed in the final program

- 118 Delivering the Magic Bullet: The Role of Transporters in Rational Drug Design.
WALLACE LMJ, AJITH SN, AL-SALABI MI, BURCHMORE RJS, CANDLISH D, GOULD MK, JABEEN I, **DE KONING, H.P.**
University of Glasgow, Glasgow, UK.
- 318 Receptor-Mediated Endocytosis: A Pathway for Drug Delivery and a Target for Drug Design.
V MARSHANSKY
Program in Membrane Biology, MGH, Department of Medicine, Harvard Medical School, Boston, MA, USA.
- 308 Interest of Fluorine-19 Nuclear Magnetic Resonance (¹⁹F NMR) to Detect, Identify and Quantify New Metabolites of Fluorinated Antifungal and Anticancer Drugs in Humans.
MALET-MARTINO M, MARTINO R, GILARD V, DESMOULIN F
Biomedical NMR Group, SPCMIB Laboratory, Paul Sabatier University, Toulouse, France.
- 126 Oral Vaccination Against Typhoid Fever.
Guido Dietrich
Berna Biotech Ltd, Berne, Switzerland.